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“Hot as a hare, blind as a bat, dry as a bone, red as a beet, and mad as a hatter.” 
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Tiivistelmä  Referat Abstract 
Anticholinergic medicines are commonly used to treat e.g. incontinence. These medicines have 
side effects, which may cause and also exacerbate e.g. dryness of the mouth, increased heart 
rate, and even cognitive impairment. Older people may be more at risk for these side effects as 
they may be experiencing similar symptoms as a natural effect of aging, and because they may 
be using several medicines causing these effects. Older people often have a high medicine 
burden and also a high disease burden. Measuring anticholinergic effects to change medicine 
regimens and to reduce the symptoms is difficult as there is no golden standard method. 
 
This thesis investigated the published methods available for estimating anticholinergic burden in 
the literature review part, and used one anticholinergic scoring system, the Anticholinergic Risk 
Scale, in a cross-sectional study to test the effects of anticholinergics on mortality in 1004 older 
institutionalised patients from Helsinki area public hospitals. Cross-tabulations and Kruskal-
Wallis or Chi square methods were used to detect differences between variables such as 
nutritional status or certain diagnoses when the patients were stratified according to their 
anticholinergic use. Cox Proportional Hazard regression, the logrank test and Kaplan-Meier 
curve were used to investigate the effects of anticholinergics on 5-year all-cause mortality. 
 
An in vitro serum assay and seven anticholinergic scoring systems were identified in the 
literature search. Also, 17 anticholinergic lists were identified, which covered 278 medicines, of 
which 21 appeared on at least eight of the lists. In the empirical study, the women’s (n = 745) 
mean (± SD) age was 83.35 (± 9.99) years, and they were older than the men (n = 241, mean 
age ± SD 75.11 ± 11.48, p < 0.001). The 1004 patients (response rate 70 %) were using a mean 
(± SD) number of 7.1 ± 3.4 regular medicines (range 0-20). 455 patients used no 
anticholinergics, 363 had some anticholinergic burden (score 1 or 2), and 186 had a high burden, 
with anticholinergic scores of 3 or more. The mean ARS score (± SD) was 1.2 ± 1.5 (range  
0-10). When three anticholinergic lists were compared, all three lists identified only 280/791 of 
patients who were anticholinergic users according to at least one list. No association was found 
between anticholinergic medicine use and mortality. 
 
There are several methods available for measuring anticholinergic burden, but there is a need 
for a consensus method. This was highlighted by the lack of agreement on medicines on 
different lists and when three anticholinergic lists tested identified different patients when 
compared to each other. Anticholinergic use was common in this frail, older patient sample, but 
no effect on mortality was shown in this study setting. The cross-sectional nature of the data 
limits the reliability of the study, and any conclusions beyond older patients in Helsinki area must 
be done very cautiously. Future research should define anticholinergics better and investigate 
their possible effect on mortality in a prospective, randomised, and controlled setting.  
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Tiivistelmä  Referat Abstract 
Antikolinergisiä lääkkeitä käytetään yleisesti mm. inkontinenssin hoitoon. Näillä lääkkeillä on 
sivuvaikutuksia, jotka voivat aiheuttaa tai pahentaa esim. suun kuivumista, sydämentykytystä 
tai jopa kognitiivisia kykyjä. Vanhukset saattavat kärsiä näistä oireista osana luonnollista 
vanhenemista, ja heillä saattaa olla käytössään useita antikolinergisia lääkkeitä. Tästä johtuen 
heillä saattaa olla suurempi riski kärsiä näistä sivuvaikutuksista. Vanhuksilla on usein suuri 
lääke- ja sairaustaakka. Antikolinergisten vaikutusten mittaaminen lääkehoitojen muuttamiseksi 
ja oireiden vähentämiseksi on vaikeaa, koska saatavilla ei ole referenssimenetelmää. 
 
Tässä tutkimuksessa tutkittiin kirjallisuusosiossa antikolinergisten lääkkeiden taakan 
mittaamiseen käytettäviä menetelmiä. Erästä tällaista menetelmää, Anticholinergic Risk Scalea 
(ARS) käytettiin läpileikkaustutkimuksessa arvioitaessa antikolinergien käytön vaikutusta 
kuolleisuuteen potilasaineistolla, jossa mukana oli 1004 laitoshoidossa olevaa vanhusta 
Helsingin alueen julkisista sairaaloista. Ristiintaulukoinnin ja Kruskal-Wallisin sekä Khin neliö  
-testien avulla tutkittiin eri antikolinergisen taakan omaavien ihmisten eroja 
mm.ravitsemustilassa ja tietyissä diagnooseissa. Coxin suhteellisen riskin regressio-
menetelmällä, logrank-testillä ja Kaplan-Meier-kuvaajalla tutkittiin antikolinergien vaikutusta 
kuolleisuuteen viiden vuoden tarkasteluvälillä. 
 
Kirjallisuushaussa löytyi in vitro seerumimääritys sekä 7 antikolinergien pisteytysmenetelmää. 
Lisäksi löydettiin 17 antikolinergilistaa, joilla oli yhteensä 278 lääkeainetta, joista 21 löytyi 
vähintään kahdeksalta listalta.Kokeellisessa tutkimuksessa naisten (n = 745) keski-ikä oli 83.35 
(± 9.99, SD) vuotta, he olivat vanhempia kuin miehet (n = 241, keski-ikä  75.11 ± 11.48 vuotta, 
p < 0.001). Tutkimuksen 1004 osallistujaa (vastaus-% 70) käytti 7.1 ± 3.4 lääkettä 
säännöllisesti (vaihteluväli 0-20). 455 potilasta ei käyttänyt lainkaan antikolinergeja, 363 käytti 
jonkin verran (pisteysaldo 1 tai 2), ja 186 käytti paljon (pistesaldo 3 tai yli). Keskimääräinen 
ARS-pistemäärä oli 1.2 ± 1.5 (vaihteluväli 0-10). Verrattaessa kolmea antikolinergilistaa 
toisiinsa, vain 280/791 potilasta tunnistettiin antikolinergien käyttäjäksi yhtä aikaa kolmen listan 
avulla. Antikollinergien käytöllä ei ollut tässä tutkimuksessa yhteyttä kuolleisuuteen.   
 
Useasta antikolinergikuormitusta mittaavasta menetelmästä huolimatta tarvitaan konsensus-
menetelmä. Tätä korosti tutkimuksessa havaittu vaihtelu siinä, mitkä lääkkeet olivat 
antikolinergisilla listoilla, ja miten eri listat tunnistivat eri potilaita antikolinergien käyttäjiksi. 
Tämä heikkokuntoinen vanhusväestö käytti yleisesti antikolinergeja, mutta yhteyttä 
kuolleisuuteen ei löydetty tässä koeasetelmassa. Tutkimuksen läpileikkausrakenne rajoittaa 
sen luotettavuutta, eikä tuloksia voida varauksetta yleistää muihin potilasryhmiin. Tulevissa 
tutkimuksissa tulisi keskittyä määrittelemään antikolinergit paremmin, ja tutkia niiden 
mahdollista vaikutusta kuolleisuuteen prospektiivisissa, satunnaistetuissa ja kontrolloiduissa 
tutkimuksissa. 
Avainsanat Nyckelord Keywords 
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1 INTRODUCTION 
 
The proportion of over 65-year-olds is increasing in many developed countries, including 
Finland (Koskinen et al 2006; Statistics Finland 2008). Incidence rates of many diseases 
will most likely decline and treatments will be improved, but the sheer increasing number 
of the older population will require more health care resources (Koskinen et al 2006). This 
challenges health care services as the amount of people in need of long-term care increases.  
 
There are several special challenges in geriatric care. Older people may have several 
comorbidities and a heavy ailment and medicine burden (Spinewine et al 2005). Many 
conditions such as Parkinson’s disease, cerebrovascular changes, multiple sclerosis, and 
schizophrenia may increase the risk of cognitive impairment in this age group (De Ridder 
2006). Sometimes changes in mental status, such as hallucinations and delirium may go 
unnoticed for longer periods of time in older patients as they may not be able to voice 
complaints about discomfort, and reversible reasons behind the changes such as certain 
medicines may be overlooked (De Ridder 2006; Raivio et al 2006). A patronizing or 
“ageist” attitude among caregivers concerning older patients may be a problem, as well as 
frequent changes in treating physicians, making acute care the priority while long-term 
treatment considerations may be overlooked (Spinewine et al 2005). Transferring medicine 
data of older patients between primary and secondary care may be limited, and shared 
decision making throughout the chain of treatment may be a challenge. 
 
This thesis investigates the burden of anticholinergics, a group of medicines with 
potentially harmful side effects in older patients. Anticholinergic medicines block 
muscarinic receptors, and common indications for these medicines include incontinence, 
Parkinson’s disease and glaucoma (Tune and Coyle 1980; Mintzer and Burns 2000). Dry 
mouth, constipation and blurred vision are common side effects caused by anticholinergics, 
and they have the potential to cause impairment in cognition and problems in everyday 
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functions of patients, e.g. dizziness and loss of balance (Mintzer and Burns 2000; Ancelin 
et al 2006). Older patients may be more at risk for adverse effects from anticholinergics, as 
they may have some of these symptoms already as a natural effect of aging. Methods for 
estimating anticholinergic burden i.e. the sum of anticholinergic effects or medicines are 
reviewed in this thesis, and one anticholinergic scoring system is used to investigate 
possible effects of these medicines on mortality in older nursing home patients. 
 
 
2 BACKGROUND 
 
Older people in Finland commonly use many medicines at the same time, as average 
nursing home residents over the age of 65 or 70 use seven to nine medicines concomitantly 
(Suominen et al 2005; Raivio et al 2006). Overmedication may be a problem in older 
patients but having several medicines at the same time may be clinically sensible (Hanlon 
et al 2001). Polypharmacy or having multiple medicines at the same time can be defined as 
using nine or more medicines concomitantly, as people with such a medicine burden are 
more likely to be exposed to unnecessary medicines (Hajjar et al 2005). A common 
problem associated with polypharmacy is undermedication, e.g. when not enough laxatives 
are used to treat constipation caused by opioids or no stomach protecting agents are used 
with non-steroidal anti-inflammatory drugs (NSAID) (Kuijpers et al 2008). Controlling for 
possible interactions of medicines, either pharmacodynamic or kinetic, may be more 
difficult in cases where there are several medicines being used for possibly several different 
indications.  
 
2.1  Care of older people in Finland 
 
The national framework for high-quality care and services for older people sets the standard 
and works as an aide for planning the care of older people in the municipalities of Finland  
(Ministry of Social Affairs and Health 2001). Local and regional authorities use the 
framework as a base to develop services to their local older inhabitants according to what 
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their needs are. The Finnish system encourages older people to live independently at home 
in a familiar environment for as long as possible, offering community-based or home 
services to support this. Nursing homes and other institutional care facilities should be as 
safe and home-like as possible, to maintain and promote the functional capacity of their 
residents.  
 
2.2 Older people as medicine users – challenges and opportunities for better treatment 
 
Starting from the early 40s, body composition starts to change, as muscle tissue is reduced 
and replaced with fat tissue, with the general fat content of the body increasing (DeVane 
and Pollock 1999). There are also changes in heart output, and subsequently also in 
intestine, renal and liver functions, partly through reduced blood flow. The overall ability 
of the body to adapt to changes is reduced, as homeostasis is impaired (DeVane and 
Pollock 1999; Hilmer et al 2007b). Clinical studies on medicines are typically performed 
on healthy younger individuals, so little is known about how medicines behave in older 
people apart from practical experience gained by individual professionals in their everyday 
practice. Older patients should be monitored closely to see whether a medicine has desired 
effects, and if it does not, it should be discontinued (Hilmer et al 2007b).  
 
Average body weight is reduced in older people, and many older institutionalised patients 
are malnourished and have very low body weight (Suominen et al 2005; Suominen et al 
2007). Therefore dosages appropriate for younger people may be too high for older 
patients. Also, frailty should be considered as a phenotype of older people, since it has 
significant effects on how medicines behave in the body (McLachlan et al 2009). Frail 
persons are typically not participants in clinical trials, and therefore form a special group of 
patients that need extra consideration when deciding on treatments. Rather than focusing on 
the genotype of the older patient, phenotypes such as frailty should be considered.  
 
Because of diminished renal and liver clearance, and because of higher fat content in the 
body, many medicines have longer half-lives than in younger patients (DeVane and Pollock 
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1999). Oral medicine absorption may be slowed down because of slower intestinal 
movements and decreased gastric acid output. Reduced plasma albumin and α1-acid 
glycoprotein concentrations may change the pharmacokinetics of acidic and basic 
medicines, respectively, as these proteins are the main binding molecules of these 
medicines in plasma. The hepatic P450 metabolic enzyme system may be affected by 
aging, making medicine dosing in older people even more difficult. Declines in hepatic 
clearance and metabolism are important factors to consider when prescribing for older 
people (Hilmer et al 2005). Older people in general are a very heterogenous group, and 
must be considered as individuals when deciding on treatment options (DeVane and 
Pollock 1999; Hilmer et al 2007b). Some very old patients have perfectly normal organ 
functions, while others have severe reductions. 
 
Older patients are a group with special needs when designing treatment strategies. 
Medication reviews may be one good tool for evaluating the appropriateness of the 
medicines in use, regardless of the age of the patient. Reviews can lead to more rational 
medicine use, described by lower scores in tools measuring medicine inappropriateness 
(Stuijt et al 2008) or discontinuation of potentially harmful medicines, e.g. hypnotics 
(Nishtala et al 2008). They may also reduce adverse effects and events like falls 
(Zermansky et al 2006). Reductions in the numbers of hospitalisations and mortality 
(Zermansky et al 2006) or costs (Altavela et al 2008) have not been proven in clinical trials 
investigating the issue. However, medication reviews may offer an opportunity to discuss 
and manage problematic issues like adherence or suboptimal treatments (Altavela et al 
2008).  
 
2.3  Identifying potentially inappropriate medicines 
 
There are several tools available to screen medicine regimens of older patients for 
potentially inappropriate medicines (Beers et al 1991; Beers 1997; Fick et al 2003; McLeod 
et al 1997; Naugler et al 2000; Socialstyrelsen 2003; Hanlon et al 1992 and 2004; Laroche 
et al 2007), but they may be difficult to adapt to care practices in other countries than those 
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where they were developed. A review of studies using the widely applied Beers criteria 
found that most studies modified the criteria to better suit their settings (Aparasu and Mort 
2000). The predictive properties of the Beers criteria to estimate possible adverse 
healthcare outcomes also need to be improved before it can be utilized for maximum 
benefits (Jano and Aparasu 2007). A comparison of the Beers criteria (Beers et al 1991; 
Beers 1997; Fick et al 2003) and the IPET tool (Naugler et al 2000) in detecting potentially 
inappropriate medicines in hospitalised older people showed that the Beers criteria had 
improved during its development, but nevertheless all inappropriate prescribing tools would 
need to be updated every three to five years (Barry et al 2006). Raivio et al (2006) found no 
differences in mortality rates when comparing institutionalised over 70-year-old Finns who 
were taking potentially inappropriate medicines according to the Beers list (Beers et al 
1991; Beers 1997; Fick et al 2003) or not taking them. However, effects on the quality of 
life of older patients may be more important than effects on mortality. The guiding thought 
in the care of older people should be preservation of functional independence (Hilmer and 
Gnjidic 2009). This means that older people should be able to live as good-quality life as 
possible independently, preferably not institutionalised, until as advanced age as possible. 
There is a clear need for better screening tools that would effectively reduce adverse events 
caused by medicines, be more adaptable to local circumstances, and offer guidance on how 
to avoid errors in geriatric care (O’Mahony and Gallagher 2008). Prescribing patterns need 
to be changed to better meet care goals, as older people may be more at risk for adverse 
events from medicines because of the high incidence of polypharmacy and changes in 
medicine metabolism in their age group (Hartikainen and Klaukka 2004). 
 
Hosia-Randell et al (2008) investigated potentially inappropriate medicine use based on the 
Beers criteria in older Finnish nursing home residents, and a usage rate of 34.9 % was 
found. Most of these patients were using only one potentially inappropriate medicine, but 
approximately every sixteenth patient of the whole study population was using more than 
one. Fialova et al (2005) investigated the use of potentially inappropriate medicines in  
11 countries in Europe. Their study focused on people aged 65 or older living at home, and 
they used the Beers Criteria (Beers et al 1991; Beers 1997; Fick et al 2003) developed in 
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the United States and the McLeod Criteria (McLeod et al 1997) developed in Canada to 
define potentially inappropriate medicines. They found a rate of 73.3 % of their Finnish 
sample to be using at least six medicines either regularly or when required, and 41.2 % to 
be using nine or more medicines. These rates observed in Finland were higher than those in 
the Czech Republic, Denmark, Iceland, Italy, the Netherlands, Norway and the United 
Kingdom. Potentially inappropriate medicines were used by 21 % (39 of 187) of the 
Finnish participants, which was close to the 20 % European average for all the countries in 
the study.  
 
Because of the potential for adverse events and reductions in the quality of life, medicine 
regimens should be screened for potentially inappropriate products (Hartikainen and 
Klaukka 2004). This may be especially important in older patients, as they usually have a 
high medicine and disease burden, making any adverse effects more pronounced. 
Anticholinergic medicines, which block muscarinic receptors, have the potential to cause 
adverse effects such as dryness in the mouth, constipation, urinary retention, and problems 
with vision (Mintzer and Burns 2000; Lieberman 2004). Some of these symptoms may be 
present as a normal effect of aging, so anticholinergic medicines may exacerbate the 
effects. It is therefore important that clinicians screen for anticholinergic effects in their 
patients, and that more research is done to investigate these effects and to improve 
medicine treatments. 
 
 
3 OBJECTIVES 
 
The literature review part of this thesis investigates anticholinergics as a medicine group 
and different ways to measure anticholinergic burden, i.e. the total amount and/or effects of 
anticholinergic medicines of the person using the medicines. As there is currently no 
international consensus on which medicines are to be considered anticholinergic and which 
not, this review will investigate current anticholinergic medicine lists and anticholinergic 
burden estimation tools available and their usefulness in clinical practice. 
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The empirical part of this thesis investigates the use of medicines with anticholinergic 
properties in older people living in nursing homes in the Helsinki area with a cross-
sectional sample. The main objective is to investigate if there is any association between 
the use of anticholinergic medicines and risk of death. Anticholinergic medicine use in this 
patient group is also investigated. 
 
 
4 METHODS 
 
This thesis has two parts: the literature review of peer-reviewed, published articles on 
methods to measure anticholinergic burden and the empirical research investigating the 
effects of anticholinergic medicine use on mortality in older people living in nursing 
homes. The research methods used in the study are described in this chapter. 
 
4.1 Methods for the literature review 
 
The literature review search was performed with the University of Helsinki NELLI Internet 
portal with the ISI Web of Science and Medline search applications. For Medline searches 
Ovid MEDLINE, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, BIOSIS 
Previews 1999 to 2008, BIOSIS Previews, Biological Abstracts, Biological Abstracts/RRM 
1989 to 2008, CAB Abstracts 1973 to Present, Drug Information Full Text December 2008, 
PsycINFO, PsycARTICLES, Nursing@Ovid, British Nursing Index and Archive, AARP 
Ageline, AMED (Allied and Complementary Medicine), EBM Reviews - ACP Journal 
Club, EBM Reviews - Cochrane Central Register of Controlled Trials, EBM Reviews - 
Cochrane Database of Systematic Reviews, EBM Reviews - Cochrane Methodology 
Register, EBM Reviews - Database of Abstracts of Reviews of Effects, EBM Reviews - 
Health Technology Assessment, EBM Reviews - NHS Economic Evaluation Database, and 
Journals@Ovid databases were included. The time frame investigated was from the starting 
date of all the databases until December 2008. 
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4.1.1 Search strategy 
 
Medical subject heading (MESH) terms for anticholinergics were obtained from the US 
National Center for Biotechnology Information’s PubMed portal. Terms used for 
anticholinergic medicines included cholinergic antagonists, cholinolytics, cholinergic 
blocking agents, acetylcholine antagonists, anticholinergic agents, anticholinergics, 
antimuscarinics, antimuscarinic agents and parasympatolytics. These terms were combined 
in the Medline search engine with the terms “physical function”, “cognitive function”, 
“mortality”, “serum anticholinergic activity”, “definition”, “elderly”, and “measurement”. 
The same terms were also used in Web of Science in different combinations. 
 
4.1.2 Data abstraction 
 
All titles and abstracts of articles found in the searches were screened for relevance to the 
thesis topic. Articles discussing anticholinergic use in older people, effects on physical and 
cognitive functions, and how to measure anticholinergic medicine effects were obtained 
and investigated further. Those articles that listed anticholinergic medicines or presented a 
way of estimating anticholinergic burden in medicine users were considered particularly 
relevant. All selected articles’ lists of references were also investigated to find more related 
articles. No formal data abstraction tables were used in this systematic literature search, and 
one researcher reviewed the articles. Some articles were used in the literature review, while 
others were used as background information for the whole thesis. Based on the literature 
search, a table of anticholinergic medicines was collected from different publications. The 
frequency of medicines appearing on different anticholinergic lists was also investigated. 
  
4.2 Methods used in the empirical research 
 
The Anticholinergic Risk Scale (ARS) tool developed by Rudolph et al (2008) was used to 
identify medicines with anticholinergic properties and the sum score of all anticholinergics 
  
9 
was calculated for each patient. This score can be used to estimate anticholinergic burden, 
and its association with mortality was investigated. 
 
4.2.1 Patient sample 
 
The study population were all the residents in 53 long-term care wards in the city of 
Helsinki public hospitals in September 2003. These hospitals serve, among other patients, 
both older patients with acute health concerns and a need for rehabilitation, and also 
nursing home residents, with a total patient base of 200,000 inhabitants (Soini et al 2004; 
Raivio et al 2007). At the time of the data collection, there were 1444 patients staying in the 
hospitals, and all the hospitals in the area were included in the study. Data collection was 
performed as part of nutrition status studies (Soini et al 2004; Suominen et al 2005; 
Suominen et al 2007). Trained nurses evaluated their patients’ nutritional status and filled 
out a questionnaire, which was based on the National Resident Assessment Instrument for 
Nursing Homes (Morris et al 1990), which was modified and translated to Finnish (Soini et 
al 2004). The questionnaire used in their study had two sections: the nutrition status section 
with 18 items (forming the Mini Nutritional Assessment, MNA), and the background 
information section with 21 items (Appendix 1). The patients’ age, gender, marital status, 
level of education, problems with eating (e.g. dry mouth), diagnoses and prescription 
medicine use were recorded as part of the background information data (Soini et al 2004). 
The Hospital District of Helsinki and Uusimaa ethics committee approved the study. 
 
As part of the background data, Charlson Comorbidity Index scores were calculated for 
patients. The Charlson Comorbidity Index is a method for describing the total 
comorbidities in a patient (Charlson et al 1987). It combines the effects of diseases, which 
are given scores weighted by their seriousness, i.e. likelihood to increase mortality and 
morbidity. It also takes into account the patient’s age, giving extra points on the Index score 
for more advanced age. The higher a Charlson Comorbidity Index score a patient has, the 
poorer their overall condition is thought to be. The index has been validated to predict long-
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term mortality, and also to predict short-term (six month) hospitalisations and mortality in 
older nursing home patients (Buntinx et al 2002). 
 
Mini Nutritional Assessment (MNA) scores were also calculated for patients. The MNA is 
a validated screening tool that attempts to identify older patients at risk for malnutrition 
(Guigoz et al 1996; Guigoz et al 2002). It investigates self-perceived health and markers of 
malnutrition, e.g. dietary intake, mobility, depression, weight loss, BMI, calf 
circumference, and mid-arm measurements with an 18-item questionnaire. A low score in 
the MNA means that the patient may be malnourished or at risk for it, and scores below 17 
are considered malnourished. 
 
4.2.2 Medicine data 
 
All patients’ prescription medicine use was recorded in an Excel file, and the data was 
coded to the level of ATC codes (Anatomical Therapeutic Chemical Classification system) 
and medicinal substances, and the medicines were marked as being used regularly or only 
when required. During the coding process misspelled names for medicines were corrected 
and different brand names for the same medicinal substance were coded to mean the same 
medicine. Medicines marked in the records as “taken when required” were excluded from 
the analysis, as were topical, ophthalmological, and otologic products. The total number of 
medicines in regular use was calculated from the file for every patient.  
 
4.2.3 Identifying anticholinergic medicines 
 
The ARS scoring system (Rudolph et al 2008) was used to identify medicines with 
anticholinergic properties. This list of anticholinergic substances includes 21 medicines that 
give three points in the scoring system, 14 medicines contributing two points, and 14 
medicines giving one point (Table 2). The higher points a medicine has, the more 
anticholinergic it is considered, and the more anticholinergic burden it adds to the patient’s 
total score. Of these 49 medicines, 34 were commercially available in Finland in 2003 
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when the study material was collected (Lääketietokeskus 2002 and 2003). The data were 
coded to give ARS points for all medicinal substances ranging from zero to three (Table 2), 
and total ARS scores were calculated for each patient by adding up all their ARS points. 
 
Three different lists of anticholinergics were used to classify all patients as either users or 
non-users of anticholinergics. If a patient was using a medicine on a given list, they were 
considered to be anticholinergic users according to that particular list. One of the lists was 
chosen because it is based on SAA measurements (Tune et al 1992 combined with its 
update, Lu and Tune 2003), one because it is based on literature (Rudolph et al 2008), and 
one because it is based on Finnish patients and medicines (Uusvaara et al 2009). 
 
 
 
Table 2. The ARS list (Rudolph et al 2008) of anticholinergic medicines and their 
availability in Finland in 2003. 
ARS points Medicines in the ARS list (those available in Finland in 2003 
underlined) 
3 
amitriptyline, atropine, benztropine, carisoprodol, chlorpheniramine, 
chlorpromazine, cyproheptadine, dicyclomine, diphenhydramine, 
fluphenazine, hydroxyzine, hyoscyamine, imipramine, meclizine, 
oxybutynin, perphenazine, promethazine, thioridazine, thiothixene, 
tizanidine, trifluoperazine 
2 
amantadine, baclofen, cetirizine, cimetidine, clozapine, cyclobenzaprine, 
desipramine, loperamide, loratadine, nortriptyline, olanzapine, 
prochlorperazine, pseudoephedrine-triprolidine, tolterodine 
1 
carbidopa-levodopa, entacapone, haloperidol, methocarbamol, 
metoclopramide, mirtazapine, paroxetine, pramipexole, quetiapine, 
ranitidine, risperidone, selegiline, trazodone, ziprasidone 
0 all other medicines 
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4.2.4 Statistical methods 
 
Patient characteristics were analysed with statistical methods and possible differences 
between groups of varying load of anticholinergics were investigated. Characteristics were 
cross-tabulated to obtain patient numbers in each group and the differences between groups 
were tested. Categorical variables were tested with the chi-squared test. These included 
being bed bound, nutritional status as defined by an MNA category, gender, being 
widowed, having studied only at primary school level, having diabetes mellitus (DM), 
coronary artery disease (CAD), acute myocardial infarction (AMI), stroke, dementia, 
depression, other psychiatric illness, Parkinson’s disease, other neurological illness, 
rheumatic disease, chronic obstructive pulmonary disease (COPD), gastric or duodenal 
ulcer, hip fracture, cancer, and the number of medicines in regular use in three categories. 
Continuous variables were tested with the Kruskal-Wallis test (comparing at least three 
variables) test, which does not require the data to be normally distributed. The continuous 
variables investigated included the length of stay in the ward, age, Charlson Comorbidity 
Index score, and the absolute number of medicines in regular use. The null hypothesis in all 
analyses was that there was no difference in these variables between patient groups with 
differing anticholinergic load. All statistical analyses were performed with the NCSS 2007 
software, and p-values less than 0.05 were considered statistically significant.  
 
The Kruskal-Wallis one-way analysis of variance (also called the H test) tests whether three 
or more independent populations are the same according to some characteristic and its 
sample distribution, or if they differ from another (Chan and Walmsley 1997). The test 
does not show which specific population group may differ or how, only if there is a 
difference in distributions between the groups compared. Sample and population 
distributions are investigated in the test, and it shows whether any observed differences are 
by chance or real differences between populations. The test is nonparametric, so it does not 
assume any distributions for the data, but it does assume that the observations analysed are 
independent. An expert must critically examine any observed differences to see whether 
they are meaningful from a clinical point of view.  
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The risk of death over a five-year time period was investigated. The null hypothesis was 
that there was no difference in survival between patient groups with varying anticholinergic 
load. Causes of death were not known for the patients, so all cause mortality was used as 
the end-point. Effects of several independent explanatory variables on the risk of death 
were investigated with the Cox Proportional Hazard method. This model estimates the sizes 
of differences between groups with logistic regression, and hazard ratios with 95 % 
confidence intervals for the included explanatory factors are obtained. Hazard ratios 
provide an estimate of how much the factors affected the risk of death, and with logistic 
regression the combined effects on risk of death could be investigated in the Cox model 
(Spruance et al 2004). The cumulative rate of mortality during the two-year follow-up was 
investigated by drawing a Kaplan-Meier curve. The Kaplan-Meier curve shows calculations 
of survival at time intervals and estimates the probability that patients who were alive at the 
beginning of a time interval were still alive at the end of it (Bland and Altman 1998). The 
logrank test was used to analyse patient data. It compares the survival of patient groups, in 
this case groups with a different anticholinergic load, and takes the whole follow-up period 
into account in the analysis (Bland and Altman 2004). The test does not give the size of any 
observed difference in survival between groups, but it shows if the difference is statistically 
significant. Clinical significance must again then be considered. 
 
 
5 LITERATURE REVIEW: METHODS FOR ESTIMATING 
ANTICHOLINERGIC BURDEN 
 
Anticholinergic medicines are a modifiable risk factor for morbidity, and identifying those 
at need for medicine regimen changes is important (Rudolph et al 2008). Estimating the 
total burden of anticholinergic medicines to a patient’s system would be useful e.g. for 
clinicians reviewing a medicine regimen or investigating patient complaints of side effects 
typical of anticholinergics. An ideal burden estimation system would take into account all 
  
14 
clinically significant anticholinergic medicines in use and their dosing (Hilmer et al 2007a). 
The patient’s clinical status and all its implications, and also individual variance in e.g. 
medicine metabolism should be considered when estimating anticholinergic burden. 
Developing such a system that would suit every patient situation is a challenge, as currently 
there is not even a universal, all-inclusive list of anticholinergic medicines available. An 
internationally accepted definition for an anticholinergic medicine is lacking as well. Rudd 
et al (2005) recommend in their review of methods to estimate anticholinergic burden that 
lists of anticholinergic medicines combined with clinical judgment are currently the best 
choice despite the lists’ lack of objectivity. This literature review chapter introduces some 
methods for determining anticholinergic burden. 
 
5.1 Anticholinergic medicines and their use in the elderly 
 
The effects of anticholinergic medicines on the body, both intended effects and side effects 
are described in the following chapters. Some of the problems with adverse effects are 
reviewed, focusing on cognitive effects and older people as the medicine users. 
 
5.1.1  Anticholinergic medicines 
 
Anticholinergic medicines block either nicotinic or muscarinic acetylcholine receptors 
either in the peripheral or central nervous system synapses or both (Peters 1989). The most 
clinically relevant are the muscarinic blockers, which can be used for a variety of clinical 
indications, e.g. to relax smooth muscle tissue. Some indications include intestinal pain, 
overactive bladder, obstructive respiratory diseases, and also prevention of extrapyramidal 
side effects in Parkinson’s disease.  
 
Muscarinic receptors are G-protein coupled receptors distributed throughout the body 
(Caulfield and Birdsall 1998). There are five receptor subtypes, and the M1 subtype is 
mainly found in the brain, sympathetic ganglia and glands. M2 is mainly found in the heart, 
hindbrain and smooth muscle, while M3 is located in smooth muscle, glands and to some 
extent the brain. M4 can mainly be found in the striatum and basal forebrain, and M5 in 
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substantia nigra and in peripheral tissues. The selectivity of anticholinergics for these five 
receptor subtypes determines whether they have adverse effects. 
 
Other medicines than actual muscarinic blockers have anticholinergic properties too (Tune 
and Coyle 1980). Some commonly used medicines that are examples of these include 
digoxin, furosemide, prednisolone, and theophylline (Tune et al 1992). Their effects are 
less well understood, but may be clinically relevant. Anticholinergic medicines are usually 
directed at peripheral targets where their effects would be useful, but depending on their 
ability to cross the blood-brain barrier, they may also block central nervous system 
muscarinic receptors, possibly leading to confusion and delirium (Tune and Egeli 1999). 
Whether central anticholinergic effects are clinically relevant may depend on individual 
variability in pharmacokinetic factors, baseline cognitive status, and the total sum of all 
anticholinergic effects (Roe et al 2002).  
 
Anticholinergics, defined as true antimuscarinics and other medicines with anticholinergic 
properties, are quite commonly used in older populations. Estimates of prevalences of using 
one or more anticholinergic medicine range from 15 % (262/1777 patients, Lechevallier-
Michel et al 2004) to 40 % (144/364 patients, Landi et al 2007) to 63 % (342/544 patients, 
Han et al 2008) in older patients, depending on the sampled population.  
 
5.1.2 Anticholinergic side effects 
 
Because only a few anticholinergics are highly specific to their intended target organs, they 
will also block muscarinic receptors in other tissues. This blocking may cause unwanted 
side effects. Typical anticholinergic side effects with varying severity of symptoms 
according to Mintzer and Burns (2000) and Lieberman (2004) are presented in Table 1. 
With increasing anticholinergic load and receptor blocking, symptoms may worsen from 
mildly irritating (e.g. dry mouth) to severe (e.g. dental decay).  
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These side effects may be more common in older than in younger users, and the symptoms 
may be attributed to other factors than medicines (Pollock 1999). And as they are common, 
they may be considered unavoidable, a “part of growing old”. Even mild anticholinergic 
effects may exacerbate some common ailments like constipation, dry mouth, glaucoma and 
urinary retention in older people (Pollock 1999), and difficulties in chewing may lead to 
malnutrition as the patient may be unable to finish her/his meal (Suominen et al 2005). Of 
particular concern is the potential for causing tachycardia in older patients with pre-existing 
myocardial ischemia (Pollock 1999). Central effects such as amnesia, delirium, or memory 
impairment are potentially more harmful for the patient, but even mild peripheral effects 
like urinary hesitancy may become important issues because they reduce the quality of life. 
 
However, anticholinergic side effects are usually reversible, and may have harmful but 
potentially avoidable effects on quality of life. For many medicines that have 
anticholinergic side effects, there is an equally effective non-anticholinergic alternative, and 
any observed side effects should warrant re-evaluations of the medicines in use (Mintzer 
and Burns 2000). When e.g. antipsychotics cause these side effects, decreasing the dose 
may be the first step, or eliminating or reducing the doses of other medicines with 
anticholinergic properties, but changing to a primary medicine with less anticholinergic 
effects may be necessary and advisable (Lieberman 2004; Mulsant et al 2004). Also, 
choosing an alternative that is more M3 receptor subtype specific may be wise. M3 
receptors are distributed more in the periphery than in the CNS, and therefore binding to 
them does not disturb cognitive functions so easily. When treating incontinence, 
darifenacin, a specific M3 blocker had fewer side effects than oxybutynin, a M1 and M3 
specific blocker that is more likely to have central anticholinergic effects (Scheife et al 
2005; Kay et al 2006). Long-term medicines should ideally be chosen so that the 
anticholinergic activity would be low to begin with, thus reducing the likelihood of having 
to change medicines during therapy because of unwanted effects. There needs to be a 
change in prescription practices, and clinicians should be more alert to anticholinergic side 
effects, especially in the most vulnerable, older demented patients. 
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Table 1. Typical anticholinergic side effects ranging from mild to severe (Mintzer and 
Burns 2000, Lieberman 2004). 
 
 
Ness et al (2006) investigated the prevalence of anticholinergic symptoms and burden, and 
adverse drug events (ADEs) from anticholinergics in 532 community-dwelling older 
veterans (97.9 % were men). Their patient sample was older than 65 years of age, using at 
least five medicines regularly, and cognitively intact. This group was thought to be at high 
risk for ADEs because of their high medicine use. Altogether 27.1 % (n = 144) of the study 
participants were using at least one anticholinergic medicine. No statistically significant 
difference was found in ADE occurrence rates reported between those who were using no 
anticholinergics and those who were using one or more. Those who used anticholinergics 
had a significantly higher mean number of anticholinergic symptoms than those who did 
not (3.1 vs. 2.5, p < 0.01). The prevalences of dry mouth and constipation were also higher 
Mild Moderate Severe 
Dryness of mouth (modest) Moderately disturbing dry mouth or thirst 
Speech problems 
Reduced appetite 
Difficulty chewing, swallowing, speaking 
Impaired perception of food texture and taste 
Mucosal damage 
Dental decay, periodontal disease, denture  
misfit 
Malnutrition  
Respiratory infection 
Mild dilatation of pupils Inability to accommodate 
Vision disturbances 
Dizziness 
Increased risk of accidents and falls, leading to  
decreased function,  Photophobia 
Exacerbation/precipitation of acute angle  
closure glaucoma 
Oesophagitis 
Reduced gastric secretions, gastric  
emptying (atony) 
Reduced peristalsis, constipation 
Faecal impaction (in constipation patients) 
Altered absorption of concomitant medications 
Paralytic ileus, pseudo-obstruction 
Urinary hesitancy Urinary retention, urinary tract infection (in  
patients with urinary hesitancy) 
Increased heart rate Conduction disturbances, supraventricular  
tachyarrhythmias 
Exacerbation of angina 
Congestive heart failure, Myocardial infarction 
Decreased sweating Thermoregulatory impairment leading to  
hyperthermia 
Drowsiness Excitement Profound restlessness and disorientation,  
agitation 
Mild amnesia 
 Confusion 
  Hallucinations, delirium 
Inability to concentrate 
 Memory impairment 
 Ataxia, muscle twitching, hyperreflexia,  
seizures 
   Exacerbation of cognitive impairment  
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in the group that used anticholinergics than in those using none (57.6 % vs. 45.6 % and 
42.4 % vs. 29.4 %, for dry mouth and constipation, respectively).  
 
5.1.3 Increased risk of cognitive impairment in older people 
 
Anticholinergic medicines are often prescribed to treat common ailments such as 
incontinence, but they may also have a negative impact on cognitive functions despite their 
supposed peripheral only mode of action (Kay et al 2005). They usually target mostly 
peripherally located muscarine receptor subtypes (M3) to actuate their effect, and either do 
not enter the CNS at all or do not bind to the CNS receptor subtypes (M1, M2), which affect 
memory and cognition. This would ensure that there are no unwanted effects on cognitive 
functions. However, it is becoming more and more apparent, that these unwanted effects do 
occur when these medicines are used, possibly because of cumulative effects, often in 
patients with multiple comorbidities.  
 
Older people may be more at risk of adverse effects on cognition caused by anticholinergic 
medicines (Kay et al 2005). Several factors may cause normally only peripherally acting 
medicines to cross the blood-brain barrier into the CNS and cause unwanted side effects 
(Figure 1). New medicines are mainly tested on younger people, so these negative effects 
may not show in clinical trials before the product comes to the market. Normal age-related 
decline in memory functions may cause older people to be more vulnerable to any effects 
on cognition that anticholinergic medicines may have. Because anticholinergics are 
frequently used in this older age group, the potential for adverse effects exists, especially 
since polypharmacy is common in older people, leading to possible cumulative effects from 
e.g. several very mildly anticholinergic medicines.  
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Figure 1. Reasons for the increased risk of cognitive impairment in older people (adapted 
from Kay et al 2005). All these cumulative issues may lead to increased sensitivity to 
anticholinergics and subsequently to an increased risk of cognitive impairment. AC = 
anticholinergic medicine, DM2 = type 2 diabetes mellitus. 
 
 
As the body ages, blood flow to many tissues and organs may be reduced (DeVane and 
Pollock 1999). Reduced liver and kidney functions and an increased body fat content may 
lead to slower medicine metabolism and elimination, thus prolonging the desired but also 
the unwanted effects in the body. Liver P450 enzymes make medicines more water-soluble, 
and as aging may reduce the enzyme activity, medicine molecules may stay more lipid-
soluble for longer, and may cross the blood-brain barrier more easily. The blood-brain 
barrier also becomes more “leaky” with advancing age, allowing bigger and more water-
soluble molecules through than in younger individuals (Kay et al 2005). Comorbidities 
such as diabetes mellitus and Parkinson’s disease may also make the barrier weaker, having 
an additive effect on medicine permeability, making it easier for agents to get into the CNS. 
reduction in the number of 
cholinergic receptors in the 
brain
blood-brain barrier
permeability
changes
comorbidities: DM2, 
cerebrovascular disease, 
Parkinson’s etc.
slower metabolism and 
drug elimination
increased risk of 
cognitive impairment
from AC load
polypharmacy
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If an older person also has multiple medicines in use, the potential for additive 
anticholinergic effects in the CNS increases.  
 
Muscarinic receptor numbers in the brain decline with aging (Kay et al 2005). This may 
make the fewer functioning receptors more vulnerable to muscarinic blocking, as a small 
amount of an anticholinergic agent may then block a larger percentage of the total amount 
of receptors than in a younger brain. When this vulnerability is combined with the effect-
prolonging factors described in the previous paragraph, the net effect may be that older 
people are more at risk for adverse effects from anticholinergics. Also, because some of the 
less M3 specific medicines may not normally cross the blood-brain barrier, their effects on 
CNS muscarinic receptors and cognition may not be identified in clinical trials using 
younger people as study subjects. They may become clinically relevant in older patients 
though, when the medicines cross the barrier and block CNS muscarinic receptors. Here 
again the receptor subtype selectivity of the medicine determines, how harmful (if at all) 
the blocking may be for cognitive functions.  
 
There are data available for the possible role of anticholinergics in cognitive decline, 
although no study so far published can be described as a large-scale, prospective, 
randomised clinical trial. Drimer et al (2004) studied the cognitive effect of discontinuing 
biperiden, an anticholinergic agent in a small-scale study. They investigated 21 older (mean 
age 65.7 years, range 60-78) institutionalised people with schizophrenia, who had been 
using the medicine for over one year. There were improvements in several tests of the 
Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), a battery of 
tests that measures different cognitive functions. The total score of the ADAS-Cog test 
battery was significantly lower (20.0 vs. 21.7, p < 0.03), showing cognitive improvement 
ten days after the discontinuation of biperiden. Cancelli et al (2008a) investigated 
anticholinergic medicines as a possible risk factor for psychosis in 230 non-randomly 
selected older Alzheimer disease patients (mean age 77 ± 6 years, range 60-93). The 
participants were stratified into anticholinergic users and non-users, and the users were 
older and taking more medicines than the non-users. The investigators determined after 
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adjusting for confounders that there was a relative risk of 2.13 (95 % confidence interval 
(CI) 1.03-4.43, p = 0.042) for psychosis for users compared to non-users. This cross-
sectional study may have overestimated the risk though, as those most likely to develop a 
psychosis may have been more likely to come to the clinic because of their symptoms. 
 
5.1.4 Effects on tools measuring cognitive function 
 
Several studies have investigated the effect of anticholinergics on overall mental 
capabilities, measuring effects with the Mini-Mental State Examination tool (MMSE). Lu 
and Tune (2003) studied the two-year effect of anticholinergic medicine use on MMSE 
scores in Alzheimer’s disease patients (n = 53 for non-users, n = 16 for users) in a small-
scale study. The results of the MMSE test at baseline and at one year did not differ between 
users and non-users, but there was a decline in MMSE results for the user group at two 
years (p = 0.032). The study was not randomized, however, and the patient groups were 
small. When Bottiggi et al (2007) replicated the same study in a bigger, unselected patient 
group (n = 300) they found no association.  
 
Lechevallier-Michel et al (2004) investigated the effects of anticholinergics on the risk of 
poor cognitive performance in 1780 older, community-dwelling individuals (mean age  
77.3 years, range 67.3-102.5 years) in a cross-sectional study. Their study did not find 
statistically significant higher odds ratios for performing more poorly in MMSE and two 
other measures of cognitive function, Benton Visual Retention Test (BVRT, measuring 
immediate visual memory) and Isaac’s Set Test (IST, assessing verbal fluency) if the 
person was using anticholinergics, compared to those who were using none. Jewart et al 
(2005) compared the MMSE scores of Alzheimer’s disease patients taking anticholinergic 
incontinence medicines and without them in a small-scale study. The same nine patients in 
the study were observed with and without the medicines, with appropriate three-week 
washout periods in between. There was a difference in MMSE scores, as they were higher 
when the patients were not using the incontinence medicines (p = 0.017). However, no 
difference was observed in another mental state assessment tool, the Alzheimer’s Disease 
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Assessment Scale (ADAS-Cog). The same patients were analysed twice in the study, and 
the patient number in the study was small, so again this could only be seen as a preliminary 
study calling for more research on the subject.  
 
Bottiggi et al (2006) examined the effect of long-term use of anticholinergics on several 
cognitive measures. MMSE results did not get poorer during the six-year follow-up, but 
there was a statistically significant difference in another tool, the Trail Making Test (TMT) 
parts A and B, measuring attention, processing speed, hand-eye coordination, visual 
scanning abilities and executive function. Those who did not use any anticholinergics 
performed better in the TMT than those who were using anticholinergics. However, the 
study did not take dosage into account, and during a six-year longitudinal study it may be 
difficult to control for all over-the-counter (OTC) medicines or herbal products that the 
patients may use, when interviews were performed only once a year.  
 
Cancelli et al (2008b) tested anticholinergic medicine use as a potential risk factor of 
cognitive decline in 750 randomly chosen older individuals (mean age 75 ± 7.0 years, range 
65-99). Use of anticholinergics was more common with advancing age, growing from  
13.0 % in the age group 65-69 to 27.4 % in the 80+ group. Anticholinergic medicine users 
were older (76.7 vs. 74.4 years, p < 0.001) than those who used no anticholinergics. They 
were also using more medicines (mean number of medicines 4 vs. 1, p < 0.001) than the 
non-users, and were more likely to have poorer results in the MMSE and another cognitive 
test, Global Deterioration Scale (GDS), having an OR of 2.30 (95 % CI 1.19-4.45,  
p =  0.013) in the MMSE and 2.59 (95 % CI 1.25-5.38, p = 0.011) compared to the non-
users.  
 
Similar results were found in the study by Ancelin et al (2006), where 372 older patients (at 
least 60 years old) were recruited by randomly chosen general practitioners. Their 
medicines were recorded at 0, 1 and 2 years time points and patient anticholinergic scores 
were assigned, and an assessment of cognitive performance and a standardised neurological 
examination were done to detect mild cognitive impairment (MCI) and dementia. The 
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cognitive assessment was also performed 8 years after the start point of the study to 
investigate long-term effects. Included in the analysis were 297 patients who had never 
during the previous year used anticholinergics, and 30 patients who were considered 
consistent users. Anticholinergic medicine use and age were the only highly significant 
predictors of mild cognitive impairment (OR 5.12; range 1.94-13.51, p = 0.001).  
Anticholinergic medicine users (those with a score of 1 or greater) did have poorer results 
in many cognitive measures, but some measures showed no effect. Comparing those with 
the highest anticholinergic score (3) with non-users did not change the situation. The study 
showed that older patients taking anticholinergic medicines had an increased risk for mild 
cognitive impairment, but not of dementia at an 8-year follow-up. The attributable risk of 
anticholinergic agents to cause MCI was 19 % in this study. This effect may not have been 
caused by anticholinergics alone, as not all known MCI risk factors were taken into account 
in the study. Also, only the general practitioners referring the patients were randomly 
chosen, the patients were not. 
 
It is difficult to interpret the results of all these different studies as most are very small-
scale and have several methodological limitations, but they seem to suggest that 
anticholinergics may have some effects on global cognitive functions as measured by the 
MMSE. These effects seem mild, however, and more studies are needed to estimate actual 
effects in patient situations, as very small changes in MMSE scores may not be clinically 
relevant. 
 
5.1.5 Delirium and possible effects of anticholinergics 
 
Another clinical state that may be affected by anticholinergics is delirium. Delirium 
involves transient changes in cognition, concentration and orientation (Clary and Krishnan 
2001). Several diagnostic tools have been developed to diagnose delirium, but different 
tools measure different aspects of the condition, making diagnosis and comparisons 
difficult (Clary and Krishnan 2001; Laurila et al 2004). Reduced ability to focus, sustain or 
shift attention and disorientation are commonly used as diagnostic criteria (Clary and 
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Krishnan 2001). The transient or fluctuating nature of the cognitive disturbances can also 
be used to identify delirious states.  
 
Lemstra et al (2003) propose the term Cholinergic Deficiency Syndrome (CDS) to describe 
a condition where central cholinergic activity is reduced. This may happen because of 
anticholinergic medicines in the CNS. The clinical symptoms, e.g. restlessness and anxiety, 
are caused by loss of attention, impaired concentration and reduced capacity to detect and 
select relevant stimuli from the surroundings. This description matches the symptoms of 
delirium well. Snow et al (2007) propose a different term, Antimuscarinic Syndrome (AS) 
to describe the same state. Their group found that an anticholinergic agent, propofol, given 
as a sedative, caused extreme inexplicable agitation and aggressiveness in a 20-year-old 
man. The symptoms cleared only after administration of physostigmine, a cholinesterase 
inhibitor, which counteracted the effects of propofol by prolonging the effect of 
acetylcholine in the synapses. This isolated case-study offers some evidence to support the 
possible connection of anticholinergics with the development of delirium. 
 
Delirium is a very complex state, with many precipitating factors like substance 
intoxication or withdrawal, infections and trauma, some of which may be rare conditions 
that are difficult to diagnose, as noted by Laurila et al (2008) in their study of Finnish 
acutely ill patients aged 70 years and older. Their study found that anticholinergic 
medicines were often involved in the development of delirium. Caeiro et al (2004) 
investigated the role of anticholinergic medicines in delirium in 22 acute stroke patients. As 
controls they had 52 non-delirious stroke patients, matched by age and gender, as older 
people generally take more medicines and because the male gender may be a risk factor of 
delirium. Delirious patients were using more anticholinergic medicines before the stroke  
(4 vs. 1, p = 0.03) and during hospitalisation (15 vs. 14, p = 0.001). The investigators’ 
predictive model had a specificity of 86.4 % (true negatives identified correctly for 
delirium, i.e. 13.6 % of false positives) and sensitivity of 100 % (all true positives identified 
correctly, no false negatives). However, despite isolated case reports (Snow et al 2007) and 
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these small-scale studies showing a possible connection with delirium and the use of 
anticholinergics, no large-scale, conclusive evidence has been presented yet. 
 
5.1.6 Concurrent use of anticholinergics and cholinesterase inhibitors  
 
Acetylcholine levels and the numbers of cholinergic neurons and receptors decrease with 
advancing age and in Alzheimer’s disease (Johnell and Fastbom 2008). To boost 
cholinergic nerve and memory functions cholinesterase inhibitors (anticholinesterases) are 
sometimes used. These medicines inhibit the cholinesterase enzyme that breaks down 
acetylcholine in the synapses, thus prolonging its effect, as metabolism is the main pathway 
to end this neurotransmitter’s activity. Anticholinergics affect the acetylcholine nerves in 
the opposite way, as they block the binding of acetylcholine. They may then counteract any 
beneficial effects that cholinesterase inhibitors may have, as if the increased acetylcholine 
in the synapse cannot bind to its receptors, its action is of no use. Concurrent use of 
anticholinergics and cholinesterase inhibitors may be a potential risk factor for suboptimal 
treatment results (Ancelin et al 2006; Johnell and Fastbom 2008). As cholinesterase 
inhibitors are used to treat Alzheimer’s disease, where the amount of cholinergic neurons is 
already reduced, any anticholinergics even in small amounts and with low affinities may 
have harmful effects. 
 
Johnell and Fastbom (2008) found in their register-based study of 731,105 Swedish 
individuals who were at least 75 years old, that anticholinergic medicine use was more 
common among those who were using cholinesterase inhibitors than those who were not  
(p < 0.001). Logistic regression that controlled for age, type of residential area and number 
of dispensed medicines showed an OR of 1.23 (95 % CI 1.13-1.35) for concurrent use for 
men and 0.88 (0.83-0.94) for women, so men were at risk to take both of these types of 
medicines at the same time. The study was cross-sectional in nature and the medicines use 
registry did not include residents in nursing homes or hospitals. OTC medicines were also 
not included. No information was available on diagnosis or possible comorbidities. Still the 
large amount of study participants was a strength of this study. Bottiggi et al (2007) found 
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in their unselected patient group (n = 300, all patients with any cholinesterase inhibitor 
included) no association with the concomitant use of anticholinergics and cholinesterase 
inhibitors and progression of Alzheimer’s disease. Their conclusion was that caution should 
be maintained but that these medicines with opposing effects do not automatically mean 
that the disease worsens. It is therefore still unclear, whether the use of anticholinergics 
should categorically be advised against in patients taking cholinesterase inhibitors. 
 
 
5.1.7 Anticholinergic effects on physical function 
 
Anticholinergic medicines may also affect physical function because of the side effects they 
cause, and the potential medical conditions that these effects may cause. Dizziness or poor 
depth perception caused by dilation of the pupils may make falls more likely (Pollock 
1999). Aizenberg et al (2002) investigated the risk of falls in older psychiatric inpatients in 
a small-scale study and how anticholinergic burden might affect the risk. Their 4-year study 
included consecutive patients admitted to a psychiatric ward, with 34 patients using 
anticholinergics (case group) and 68 controls using none. Altogether 8.2 % of all patients 
suffered a fall during their hospitalization, and those that suffered a fall did not differ from 
those who did not in mean age or distribution of psychiatric diagnosis. There were more 
women among those who fell, however, with 68 % in the case group and 39 % in the 
control group (p < 0.02). There was also a difference between the groups regarding 
anticholinergic burden score (ABS, defined as the sum of anticholinergic medicine scores, 
and each medicine was graded from one to five according to its anticholinergic potency). 
The mean ABS was 2.68 ± 1.8 for all patients in the study, and 3.25 ± 2.2 for those that fell  
(p = 0.03). This preliminary finding suggests that having a higher anticholinergic load may 
predispose a person to falls.  
 
Landi et al (2007) and Nebes et al (2007) found in their studies that anticholinergic use 
affected physical function negatively. They tested walking speed, response times, balance, 
hand grip strength, and everyday living activities, and found that having a higher 
anticholinergic burden, defined as having more anticholinergic medicines (Landi et al 
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2007) or higher serum anticholinergic activity (Nebes et al 2007) was statistically 
significantly associated with poorer performance in the tests. This may mean that the 
quality of life of older people may decrease as everyday tasks become more difficult. Cao 
et al (2008) tested the effects of anticholinergics (based on Mosby’s Drug Consult and the 
list of Peters 1989) on mobility in 932 older women. A higher anticholinergic burden was 
associated with more mobility difficulty, slower gait, more difficulty in rising, and more 
difficulty in activities of daily living (ADL), as well as poorer results in the MMSE test. 
 
5.2 Measuring individual in vitro serum anticholinergic activity 
 
Tune and Coyle (1980) were the first to develop a method for measuring in vitro 
anticholinergicity in individual patient serum samples. This radioreceptor assay called the 
Serum Anticholinergic Activity (SAA) assay, developed for measuring the combined 
anticholinergic effects in the blood, has become a gold standard over recent years despite 
its limitations (Carnahan et al 2002a).  
 
5.2.1 Serum anticholinergic activity assay – basic methodology 
 
The SAA assay uses serum as the sample matrix, and 200 µl samples are run in triplicate or 
in some cases in duplicate if the assay procedure has been well optimised in a laboratory 
(Tune and Coyle 1980). In the assay, displacement of a radiolabelled, potent anticholinergic 
antagonist tritiated quinuclidinyl benzilate (TQB) from muscarinic receptors by other 
anticholinergic agents is measured by reductions in radioactivity. TQB has affinity for all 
muscarinic receptor subtypes. Specific binding of TQB is reduced in proportion to the 
concentration of the displacing agents, giving an estimate of the total anticholinergic agent 
content in the sample.  
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Figure 2. A description of the Serum Anticholinergic Activity (SAA) assay developed by 
Tune and Coyle (1980). Briefly, rat brain tissue is homogenized and a sample is incubated 
together with a serum (patient) sample and some tritiated quinuclidinyl benzilate (TQB). 
After filtration radioactivity is measured and reductions in activity reveal the presence of 
anticholinergic agents that displace the radioactive TQB in the serum sample investigated.   
 
 
In the SAA assay, rat brain homogenate is used as a source of muscarinic receptors, and 
Chew et al (2008) report using 200-225 g of rat brain tissue at a time. 200 µl of the 
homogenate is mixed with 200 µl of serum sample and 200 µl of the TQB preparation  
(Figure 2). The assay mix is then made into 2 ml volume with buffer, and the mix is 
incubated at 22°C for 60 min (Tune and Coyle 1980). Then the mix is aspirated onto a glass 
fibre filter, which lets all free material run through but retains complexes containing the 
receptor with a bound molecule. These complexes may be radioactive if TQB is bound, or 
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non-radioactive if the bound agent is an anticholinergic substance from the serum sample 
(Figure 3). Radioactivity on the filter is measured by scintillation spectrometry, and results 
are compared to a standard curve made with known amounts of atropine, a potent 
anticholinergic agent that also displaces TQB. The levels of radioactivity represent levels of 
TQB displacement (the less radioactivity, the more TQB displaced), and the amount of 
displacing (anticholinergic) agent equals that of the amount of atropine used in a sample 
creating a similar radioactivity level. Because atropine is used as a reference molecule in all 
assays, results are given as atropine equivalents, and they are comparable between different 
anticholinergic compounds and laboratories. 
 
 
 
 
 
Figure 3. Displacement of bound tritiated quinuclidinyl benzilate (TQB) in the SAA assay. 
a) TQB bound to a muscarinic receptor in the rat brain preparation. b) An anticholinergic 
agent may displace TQB from the receptor. c) Displacement leads to reduced radioactivity, 
as unbound TQB is filtered out. 
 
 
5.2.2 Using the Serum Anticholinergic Activity assay in practice 
 
Several studies have used the SAA assay to estimate anticholinergic burden (Carnahan et al 
2002a; Chew et al 2005). Results of the studies have often been conflicting, and the 
distribution of SAA levels is skewed, i.e. there are more people with low values (Nebes et 
a) b) c) 
radioactive 
TQB 
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receptor 
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al 2007). Dose-dependent increases in SAA have been observed with anticholinergic 
medicines, but developing a tool for clinicians to e.g. estimate possible anticholinergic 
effects expected for any given dose of a medicine is difficult because of inter or intra-
individual variation (Chew et al 2006). When Mulsant et al (2003) measured the SAA 
values of 201 randomly chosen older (mean age 78.2 years) community-dwelling adults, 
they measured detectable values in 89.6 % of the cases, the median SAA value being  
1.25 nM (range 0 - 5.6 nM). MMSE test results were available for all subjects, and there 
was an association between SAA and cognition, with lower scores being associated with 
high SAA in the blood (OR 19.12; 95% CI 2.15-169.85; p = 0.008) 
 
5.2.3 Estimating central anticholinergic effects with the Serum Anticholinergic Activity 
assay 
 
The SAA assay attempts to describe the total anticholinergic burden in peripheral blood, 
but it is not clear how well if at all it can be used to estimate central anticholinergic burden. 
Plaschke et al (2007a) investigated the correlation between plasma 
(ethylenediaminetetraacetic acid, EDTA plasma) and cerebrospinal fluid (CSF) SAA levels 
in 15 non-randomly selected pre-surgical urological patients (mean age 70.4 ± 6.0 years, 
range 58-78 years). Some of these patients were using anticholinergic medicines while 
others were not, but there were no statistically significant differences between the two 
groups. Mean levels in the SAA radioreceptor assay were 2.4 ± 1.7 nM of atropine 
equivalents (range 0-5 nM) in plasma samples and 5.9 ± 2.1 nM (range 2-12 nM) in CSF 
samples. CSF levels of anticholinergic activity were 2,5 times higher than those in plasma, 
but there was a significant correlation between the two (R = 0.86, p < 0.001) so the assays 
in the two sample matrices were likely to be measuring the same parameter. Therefore the 
investigators concluded that SAA could be used to estimate central anticholinergic activity. 
Miller et al (1988) also found a correlation in their study. 
 
Thomas et al (2008) also investigated whether the SAA correlates with cerebral cholinergic 
function. Quantitative electroencephalography (qEEG) was chosen as a means to measure 
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CNS function. The qEEG measures the brain’s electric function, and centrally acting 
anticholinergics affect the alpha rhythm in the qEEG. 61 consecutive patients aged over 80 
admitted to an acute health ward were recruited to the study, and their medicines, cognitive 
test results, and qEEGs were recorded for analysis. The patients were evaluated for 
dementia, and stratified according to their mental status: cognitively unimpaired (n = 15), 
dementia (n = 31), and delirium with dementia (n = 15). No statistically significant 
differences could be found between these groups in their SAA levels, and SAA did not 
correlate with cognitive impairment (MMSE) or qEEG, even though these two reference 
parameters correlated together (p < 0.005). Based on this study SAA does not describe the 
CNS anticholinergic activity or enable detection of delirium in the acutely ill older people.  
 
Both the Plaschke et al (2007a) and Thomas et al (2008) studies are limited by a small 
patient sample. Both studies also used only a limited battery of cognitive tests to determine 
the mental status of the patients. More research is needed on SAA measurements from CSF 
as a potential tool for estimating central anticholinergic effects. 
 
5.2.4 Association of Serum Anticholinergic Activity with cognitive functions 
 
Chew et al (2005) reviewed previous studies on SAA relationship with cognition. Most 
studies had a very small patient population. There were conflicting results, but most studies 
found a relationship with higher SAA and a poorer cognitive status, even if the association 
was weak. Nevertheless, their conclusion was that treatments with anticholinergics should 
be used with caution in older, demented patients. Nebes et al (1997) hypothesized that SAA 
might in part explain the observed inter subject differences in cognitive performance, 
especially memory, that are common in depressed older patients. Their finding of effects on 
memory in patients with even a low measurable SAA level may mean that the 
anticholinergic burden needs to be taken into account when assessing cognitive 
performance in older patients.  
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Patients with dementia had significantly higher levels of SAA in the study of Mussi et al 
(1999). Another type of cerebrovascular disease affecting memory, white matter 
hyperintensities (WMH), also had a correlation to SAA levels (Nebes et al 2005). Miller et 
al (1988) compared different cognitive tests when analysing mild cognitive impairment in 
older patients of whom one half was taking and the other half was not taking scopolamine, 
a potent anticholinergic. Serum and CSF samples were analysed with the SAA assay, and 
anticholinergic activity levels were significantly higher in the scopolamine group compared 
to the placebo group with both samples. There were no differences between groups in the 
MMSE score, or the Symbol Digit Modalities score (measuring timed visual-motor 
performance), but with the Delirium Checklist score developed by the authors, scores were 
poorer for anticholinergic users. Miller et al state that in its early stages mild cognitive 
impairment is more easily managed than if it is allowed to progress to gross impairment. 
They therefore recommend SAA measurements and cognitive tests as a part of care for 
older people. Larger scale studies are needed to investigate the usefulness of SAA. 
 
5.2.5 Serum Anticholinergic Activity levels and delirium 
 
Central anticholinergic measurements have the potential to be useful diagnostic or even 
treatment guiding tools, and several studies have investigated the association of SAA with 
delirium (Chew et al 2005). SAA can be used as a delirium disease marker according to 
Marcantonio et al (2006). Milbrandt and Angus (2005) also mention SAA as a potential 
means for detecting critical illness-associated cognitive dysfunction, as several medicines 
not commonly considered to have anticholinergic properties can show such effects. The 
SAA in their opinion would better describe the total anticholinergic burden at any given 
time than calculations from a dose, as there are intra- and inter-individual differences in 
medicine metabolism.  
 
Hori et al (2005) described a 75-year-old man with Alzheimer’s disease, who was showing 
signs of dementia and delirium. When his anticholinergic medicine was stopped, his SAA 
levels dropped, the delirium resolved, and his MMSE score increased from 7 to 21 in the 
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following 28 days. Hori et al commented, that none of the medicines the patient had before 
the intervention were considered particularly anticholinergic, but nevertheless he had a high 
enough SAA value to measure. The changes in his medicine regimen had a positive effect 
on his clinical status and quality of life. The SAA assay may therefore be useful in 
detecting those patients with delirium who may benefit from medicine changes, as 
especially subclinical delirium may be hard to diagnose otherwise. 
 
Tune et al (1981) found an inverse correlation between SAA and MMSE in delirious 
patients. Mach et al (1995) found that delirium was more likely to be resolved in those 
patients who had high SAA at entry but whose anticholinergic medicines were then 
discontinued and whose SAA levels dropped. Flacker et al (1998) found the occurrence of 
delirium to be increasing as SAA levels increased. Plaschke et al (2007b) found no 
differences in SAA levels between delirious and non-delirious patients, when qEEG was 
used as a reference method to detect delirium. Also, SAA did not correlate with the qEEG. 
All these studies had limitations, as they had been not been fully randomised and they were 
very small scale, with only 77 (Flacker et al 1998), 37 (Plaschke et al 2007b), 29 (Tune et 
al 1981), or 11 (Mach et al 1995) patients. Since anticholinergic medicines are not a clear 
risk factor for delirium but rather there is an association between the two, interpretation of 
results is difficult (Carnahan et al 2002a). Delirious patients may be sicker and using more 
medicines, so SAA may not be independently associated with delirium (Tune and Egeli 
1999). As a conclusion, the SAA test cannot be used as a diagnostic tool to detect the 
presence or absence of delirium, but may be useful as a tool to identify delirious patients 
whose symptoms may be medicine induced (Mach et al 1995).  
 
5.2.6 Limitations of the Serum Anticholinergic Activity assay 
 
There are some methodological problems with the SAA assay, as it is not internationally 
standardised and it is not clearly defined, what it is that the assay is measuring (Carnahan et 
al 2002a). The assay measures binding to central muscarinic receptor subtypes more than to 
peripheral, M3 and M5 subtypes (Chew et al 2006). Reductions in SAA levels do not always 
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coincide with discontinuation of anticholinergic medicines, and this clouds the issue 
further, as there are other factors affecting SAA as well (Carnahan et al 2002a). It is also 
not available as a commercial kit, and the rat brain preparation needs to be prepared in-
house before performing the assay. This may generate differences in assay performance, as 
every laboratory needs to validate the method in their own respective conditions. This 
makes reproducibility and precision an issue, as if within day and between days variation in 
reproducibility is not limited, results may vary between assay runs and laboratories (Bylund 
and Toews 1993; Junghans 1996). Also, since the TQB tracer is radioactive, it has a limited 
shelf life, and batch-to-batch variations in the commercial product may add to possible 
reproducibility problems.  
 
The reported limit of detection (lowest theoretical, or in some cases actual concentration 
that can be measured) for the SAA assay ranges from 0.25 nM (pmol/ml, Mulsant et al 
2003) to 0.5 nM (Thomas et al 2008). The assay linear range has been reported to range 
from 0.50 to 25.00 nM (Mulsant et al 2003), but also a much broader measuring range from 
0.5 to 250 nM has been reported (Chew et al 2008). Intra-assay reproducibility (CV %) has 
been reported to be less than 12 % (Mulsant et al 2003) or less than 9 % (Thomas et al 
2008). Inter-assay reproducibility is reported as less than 12 % (Mulsant et al 2003). Mussi 
et al (1999) report a precision of 4.1 % but do not report which parameter they are 
describing. Intra- and inter-assay accuracies (i.e. recovery of spiked standard from serum) 
have been reported to be 93-109 % and 95-105 %, respectively (Thomas et al 2008). Tune 
and Coyle (1980) describe in their original article that they use a total volume of 2 ml for 
the assay, but in a following report (Tune et al 1981) they use a total volume of 1.2 ml. This 
may or may not affect TQB binding and assay results as in the larger assay volume serum is 
diluted more and the concentration of proteins is lower. Other groups using the SAA assay 
often do not mention, which total volume they are using. Carnahan et al (2002b) compared 
SAA parameters from different studies, and the results were showing clear differences 
between laboratories. However, as an atropine standard curve is always run in parallel with 
the assay, changing parameters may be controlled for through the standard. 
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One of the problems with a lack of standardisation is that some researchers use plasma 
samples rather than serum (e.g. Plaschke et al, 2007a: EDTA-plasma, Flacker et al 1998: 
heparin plasma). This may cause differences in receptor binding, as Tune and Coyle (1980) 
noticed a matrix effect even in their original article, and they believed this effect to be 
caused by proteins in serum. Proteins may reduce the binding of TQB, potentially leading 
to more displacement and subsequently an overestimation of anticholinergicity in the 
sample. Plasma contains all clotting factors which serum does not, so the protein content 
and possibly also binding interference may be higher in plasma samples (Toldy et al 2005). 
This may cause discrepancies between results in different laboratories as noted by 
Carnahan et al (2002b), especially if a medicine molecule tends to bind to serum proteins in 
a living human subject, and its binding affinity (anticholinergic activity) is being 
determined in a sample of pure medicinal substance. Aaltonen et al (1984) tested the 
sample matrix effect while developing a similar TQB binding assay for atropine, and found 
plasma proteins to reduce binding by only up to 2 %. Plasma interference may therefore not 
be relevant in practice.  
 
Because results from the SAA assay are an estimate of total displacement of TQB from the 
receptors, interfering agonists in the sample may affect the results by falsely increasing 
measured displacement, and the number of potentially anticholinergic medicines does not 
necessarily correlate with measured anticholinergic activity (Tune et al 1981; Carnahan et 
al 2002a; Mulsant et al 2004; Plaschke et al 2007a; Chew et al 2008). Flacker and Wei 
(2001) found endogenous anticholinergic substances that are likely to exist in older, acutely 
ill patients. They measured the SAA of ten older patients admitted to a health clinic, and 
who had not been using any anticholinergic medicines for the past seven days, which was 
considered a long enough time for any interfering anticholinergic metabolites to be 
eliminated. Patient samples and buffer samples spiked separately with therapeutic 
concentrations of all the medicines that the patients were using were analysed with the 
radioreceptor assay. Eight of the ten patients had measurable SAA levels (mean 0.69 ± 0.52 
nM, range 0.23-1.72 nM) even though none of the buffer samples that were spiked with the 
medicinal substances they were using had measurable SAA. The measured levels were very 
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low and close to the detection limit of the assay, however, so the results may not be reliable 
and reproducible. However, according to literature there are some endogenous substances 
that can bind to cholinergic receptors and block the binding of other molecules. These 
include dynorphin A, myelin basic protein, and protamine. If substances like these interfere 
with the assay, it may explain e.g. some of the conflicting results in studies where the 
relationship between anticholinergic medicine use and delirium was investigated.  
 
Determining SAA value tables for standard medicine solutions as published by Tune et al 
(1992) can be misleading, as having two medical substances with different SAA values 
does not mean that the other one is more anticholinergic, even if it has a higher SAA value 
(Carnahan et al 2002a). The same 10 nM standard solutions that have been used for every 
medicinal substance to determine “reference” SAA values may not occur in clinical practise 
or be clinically meaningful. Different medicinal substances have different degrees of 
protein binding, metabolism, and elimination, and do not appear in same concentrations as 
others in the blood. Medicine penetration into the CNS is a confounding factor too, as it is 
not known how well certain medicines and their metabolites penetrate the blood-brain 
barrier, and there are likely to be changes in penetration rates with advancing age and 
between-person variation. As the rat brain preparation in the assay contains mostly M1, M2 
and M4 muscarinic receptors, which are located mostly in the brain in humans too, the 
assay may be less sensitive to those medicines that bind to the more peripherally distributed 
M3 and M5 subtypes (Chew et al 2008). The blockade of these two more peripheral 
subtypes does not seem to harm cognitive functions as much as blockade of the others, so 
this binding to M3 and M5 could be considered a desirable feature in medicine molecules. 
The usefulness of the SAA assay for measuring this binding in clinical research is unsure, 
however. 
 
Despite its limitations, the SAA assay has been widely used in studies. The reason behind 
this may be its ease of use when only a blood sample is required from the patient, despite 
the assay requiring special instruments and radioactive reagents. Its clinical usefulness 
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remains unclear despite decades of investigational use, as it has not been used in routine 
clinical practice. 
 
5.3 Anticholinergic medicine scoring systems and lists  
 
A simple assessment method of anticholinergic burden is needed, but serum measurements 
have limitations, as the rate of brain penetration of many medicines is unknown. Taking 
samples from CSF or other CNS tissue is difficult and time-consuming, sometimes 
impossible or ethically unacceptable because of the risks involved in sampling (Minzenberg 
et al 2004). The SAA assay is far from perfect, and it requires blood samples and a 
laboratory to analyse them, which may not always be practical. It is still currently a 
relatively widely tested method despite its limitations, and it is often used as a comparison 
method when alternative tools are being developed to estimate anticholinergic burden. 
Simply summing up the amount of anticholinergic medicines a person has does not 
describe their anticholinergic burden accurately enough, as different medicines have 
different anticholinergic effectiveness (Carnahan et al 2002a). Many tools have been 
developed and published fairly recently, and they have attempted to solve this problem by 
grading anticholinergics. These tools have not yet been tested thoroughly for usefulness in 
everyday clinical practise with unselected patients. Some of these tools are presented in the 
following chapters. 
 
5.3.1 Anticholinergic rating scale 
 
Carnahan et al (2002b) developed an anticholinergic rating scale and compared it with the 
SAA assay by assessing 98 older nursing home residents (mean age 86.8 ± 7 years, range 
68-106) with both tools. The investigators based their work on an anticholinergic scoring 
system developed previously by Han et al (2001). This previous scoring system was 
updated and modified by three psychiatric pharmacists if there was a need for change 
arising from recent literature. The modified scores were significantly associated with SAA  
(p < 0.01), but the scores only explained 7 % of the variance in SAA levels. This low level 
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of explanation was thought to be because medicine dosage was not included in the scoring. 
Taking the dose into account is difficult, however, as the serum levels of any given 
medicine are not constant, and dose alone does not describe the situation in the blood. 
Medicines on this developed list were given scores of 0, 1, 2 or 3 depending on their 
anticholinergicity, but the authors note that this probably does not describe the actual 
relative potencies when these medicines are compared to each other. Also, since the list is 
based on expert opinion as well as the literature, it may not be free of bias. 
 
5.3.2 The combined pharmacological and clinical index  
 
Minzenberg et al (2004) developed a method where they combined a pharmacological and 
a clinical index to estimate the relative anticholinergic potency of psychotropic medicines. 
In their study they enrolled 106 outpatients with diagnosed schizophrenia, and used 
cognitive tests to evaluate their mental status. As a comparison they used a matched group 
of 50 healthy volunteers with no history of schizophrenia. Based on a thorough literature 
review the investigators calculated the relative benztropine (a centrally acting 
anticholinergic agent) equivalents for all the medicines for which they could find a brain 
tissue muscarinic receptor affinity value. This benztropine equivalence would serve as the 
Pharmacological Index. The Clinical Index was developed by having ten psychiatrists rate 
the same medicines by comparison to 1 mg of benztropine, based on their experiences of 
patient complaints of anticholinergic symptoms such as dry mouth. A mean anticholinergic 
potency value was then calculated from these gradings for each medicine. When these two 
indexes were compared to each other in the patient population, a good correlation was 
found (R = 0.80; p<0.0001). Both indexes were significantly related to inferior performance 
in the cognitive tests used, and no significant difference was observed between the indexes. 
There were limitations in the study, e.g. the ten psychiatrists had prior knowledge of in 
vitro receptor binding activities for the medicines, which may have introduced bias. Patient 
selection was not randomised, so people who were less likely to participate in studies for 
e.g. various personal reasons may have been underrepresented. Also, the Clinical Index is 
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based on peripheral symptoms, not central, as there is no accepted measure of central 
anticholinergic activity. This limits its usefulness in estimating central effects. 
 
5.3.3 The Anticholinergic Drug Scale (ADS)  
 
Carnahan et al (2006) proposed a scoring method, the Anticholinergic Drug Scale (ADS) 
for estimating anticholinergic burden. They proposed it for specifically choosing which 
medicines could be considered for discontinuation in those cases where a high 
anticholinergic load was present. In this study the previously published anticholinergic drug 
rating scale (Carnahan et al 2002b) was updated to reflect dosage, and its functionality was 
tested with the same patient sample as in the original article, using the SAA as a reference 
method. Anticholinergic scores were calculated for the 201 older patients (mean age  
86 ± 7 years, range 64-102 years) based on their regular and when required medicines taken 
on the day of the blood sampling. If a medicine was mentioned as being taken regularly and 
when required, it was included twice in the scoring.  
 
As an update to the previous scoring system, dose was taken into account for the more 
potent level 2 and 3 anticholinergics. FDA maximum recommended daily doses (MRDD) 
for adults were used as a basis for grading, and no special dosing measures for geriatric 
patients were taken into account. This was a limitation of the study, as older patients may 
be prescribed lower doses, and this leads to underestimations of the dose weights. Patients’ 
scores for level 2 or 3 medicines were weighted based on the ratio of their daily dosage 
compared to the MRDD. For level 0 or 1 medicines there was no adjustment for dose. If the 
daily dose was less than or equal to one third of the MRDD, the dose weight was 1. If it 
was more than one third but less than or equal to two thirds of the MRDD, the dose weight 
was 2. If the dose was greater than two thirds or equal to the MRDD, the weight was 3. For 
doses greater than the MRDD the weight was 4. Dose-adjusted scores were calculated for 
level 2 and 3 medicines by multiplying the anticholinergic score by the determined dose 
weight.  
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The ADS total scores were significantly associated with SAA (p < 0.0001). The median 
ADS total score was 2 (range 0-11), and the median dose-adjusted ADS total score was 3 
(range 0-25). Adjusting for dose did not offer any improvements in how well the score 
predicted SAA levels, and the 0-1-2-3 grading used in the older version (Carnahan et al 
2002b) was ultimately deemed adequate for analysis. The authors thought that the ADS’s 
low level of explaining variance in SAA (7 %) was due to differences in medicine 
potencies within scoring groups, as not all medicines in e.g. level 3 medicines have the 
same anticholinergic potency. A scoring system of 0-1-2-3 may not be optimal or reflect 
real relative potencies. Their previous conclusion (Carnahan et al 2002b) of the importance 
of dose was thus discarded. These new ADS scores were associated with SAA, and could 
be applied to any medicine list, depending on availability in any country. Also, this method 
did not require blood samples to be taken as the SAA assay does. The ADS could be used 
as an aide to choose which medicines to target to reduce anticholinergic burden, but the 
authors concluded that this warranted more study.  
 
Low et al (2008) tested the ADS developed by Carnahan et al (2006) in their study of 2058 
randomly selected young-old (aged 60-64 at baseline) community-dwelling individuals. 
This was a longitudinal cohort study, with a follow-up time of 4 years. Participants were 
tested with several tools measuring cognitive functions (Mini Mental-State Examination, 
speed of information processing, simple reaction time, verbal intelligence, immediate and 
delayed recall) at baseline and at 4 years. Patients with dementia, brain tumours, brain 
infections, stroke and cancer were excluded from the study, as they were considered to be 
especially vulnerable to anticholinergic effects. These excluded participants were using 
more anticholinergics then those included in the study analysis (22.6 % vs. 15.9 %,  
p = 0.037), which limits the study reliability. This analysis found evidence that 
anticholinergic medicine use, measured by the ADS score, was more common in women 
than in men (56.1 % of users were women vs. 46.8 % of non-users), and that the prevalence 
of use in the whole study population was approximately 15 %. Use of anticholinergic 
medicines was not associated with greater decline in any cognitive tests, but complex 
attention was affected negatively in one of the tests (p = 0.005). This small difference 
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detected may not be clinically relevant though, as the authors note. This study used the 
previously developed ADS to identify patients using anticholinergics, but whether the ADS 
was used to its full extent as participants were only divided by use/non-use only remains 
unclear. The random nature of the patient sample and the large number of participants are 
the strengths of this study, as they mimic real life clinical situations.  
 
5.3.4 The Ancelin anticholinergic scoring system  
 
Ancelin et al (2006) developed an anticholinergic scoring system based on anticholinergic 
potency values available in the literature for medicines in the SAA assay, combined with an 
expert group (pharmacologist, physician, and biologist) clinical opinion of anticholinergic 
potency. The result scoring system gives individual patients a score from 0 to 3, 0 meaning 
no anticholinergic medicines in use, 1 meaning medicines in use with no likely 
anticholinergic effect, 2 meaning medicines in use with a low effect, and 3 meaning that 
there are medicines with high anticholinergic effect in use. This system of scoring patients 
rather than medicines is different to the other grading tools.  
 
To test the tool, all prescription, OTC and herbal and other medicine use of a group of 
patients over 60 years of age were recorded at 0, 1 and 2 years time points (Ancelin et al 
2006). Those who had an anticholinergic score of one or greater had poorer test results in 
some tests measuring cognitive performance. The functionality of the tool was good in this 
study as its developers were using it, but more usage is needed to estimate its usefulness in 
routine practice. 
 
5.3.5 The Han anticholinergic scoring system  
 
Han et al (2008) evaluated an anticholinergic medicine scoring system based on clinical 
evaluations by geriatricians. Their study included 544 men aged 65 and older with 
diagnosed hypertension requiring constant pharmacotherapy, typically with several 
medicines at the same time. Cumulative exposure to anticholinergics over the preceding  
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12 months was determined, and the anticholinergic medicines were given scores from  
0 to 3 according to the literature and how strong their anticholinergic effects were 
considered by a group of three independently evaluating geriatricians. This new list was an 
update of their previous study where a similar scoring system and list was created based on 
expert opinion of three geriatric psychiatrists (Han et al 2001).  
 
During the 2-year follow-up period, total anticholinergic burden (defined as cumulative 
anticholinergic scores) over the previous year was significantly associated with poor 
performance in tasks that tested memory and executive function (p = 0.002 - 0.04, 
depending on the model used) (Han et al 2008). The adverse effect would amount to a 0.30-
point deficit in the memory test and 0.10 point deficit in the executive decision test per one 
unit (score point) of anticholinergic burden per 3 months of medicine use. The clinical 
significance of these deficits was not explored. This would be important, because clinical 
importance and statistical significance do not always mean the same thing (Altman and 
Bland 1995). This deficit effect was three times (memory task) or one times (executive 
task) greater than the effect of non-anticholinergic medicines. Limitations of this study 
included the selected patient population (hypertension patients from a Veteran’s Affairs 
clinic in Connecticut, USA) that may not be representative of other population groups. 
Also, the anticholinergic scoring system was based on three geriatricians’ opinions only, 
and not on e.g. a consensus panel. Expert opinion may have been formed based on clinical 
evidence, but for some medicines with suspected anticholinergic effects there is not much 
peer-reviewed, published evidence available to form an opinion. 
 
5.3.6 The Anticholinergic Risk Scale (ARS) 
 
Rudolph et al (2008) developed a scoring system for anticholinergic medicines, the 
Anticholinergic Risk Scale (ARS). The tool was developed by having a geriatrician and 
two specialist geriatric pharmacists grade the anticholinergicity of 500 most prescribed 
medicines in the Veterans Affairs Boston Healthcare System with a score of either 0 (no 
anticholinergic effect or a limited effect), 1 (moderate effect), 2 (strong effect) or 3 (very 
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strong effect). Grading was done based on affinity data of the medicines for muscarinic 
receptors, FDA-published rates of their anticholinergic side effects, and literature regarding 
the adverse effects. Literature values of affinity constants mostly give values only for 
affinity to the M1 receptor, which is found in the CNS, and constants for the more 
peripheral M3 and M5 are not given (Kwatra 2008). This may limit the usefulness of the 
ARS score, as it makes estimation of peripheral effects more difficult. Median scores were 
given if there was disagreement on a medicine’s score among the raters. All topical, 
ophthalmologic, otologic, and inhaled medicines were excluded. The finished scores could 
then be used to give points for all medicines that the analysed person was using, and a total 
sum of these would be the final ARS score.  
 
The ARS system was tested on older patients. The study combined a retrospective cohort of 
132 consecutive patients (mean age 78.7 ± 5.3 years) of a health clinic, and a prospective 
cohort of 117 male patients (mean age 71.5 ± 11.6 years), attending primary care clinics in 
the same settings (Rudolph et al 2008). Each patient’s medicines were used to give her/him 
an ARS score. All anticholinergic adverse side effects were also recorded in interviews. 
Each effect was given a score of 1 (hence not necessarily describing their relative severity), 
and the sum of adverse effects was calculated for each patient, with peripheral and central 
effects summed separately.  
 
In the studied patients, higher ARS scores were associated with increased risk of both 
peripheral and central anticholinergic adverse effects in the prospective cohort, and an 
increased risk of central adverse effects in the retrospective cohort (Rudolph et al 2008). 
After the results were adjusted for age and total number of medicines, in the retrospective 
patients the relative risk of any anticholinergic adverse effects was 1.3 (95 % CI 1.1-1.6) 
and in the prospective patients it was 1.9 (95 % CI 1.5-2.5). The study showed the ARS to 
be a useful tool in identifying possible problems with anticholinergic burden in older 
patients. The ARS scoring does not take into account dosage, however, and as the authors 
state, doing the ARS calculations during a patient encounter can be difficult as it is time-
consuming. It could be used in electronic databases though, e.g. in medicine records. 
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Because most of the patient sample was male, and the patients were a select group, veterans 
from the Boston area with hypertension, further studies are recommended by the authors to 
establish its usefulness in unselected patients in clinical situations. Hilmer and Abernethy 
(2008) commented that the ARS weighting of the medicines into classes of 0 to 3 was done 
based on data from all kinds of patients. Therefore it is more strongly associated with 
effects in stronger primary care patients rather than frail patients in geriatric care. 
 
5.3.7 The Drug Burden Index  
 
Hilmer et al (2007a) devised a drug burden index that incorporates both anticholinergic and 
sedative burden. The total drug burden (TDB) is calculated by summing anticholinergic and 
sedative effects of medicines. Their group used two US pharmacopoeias to identify 
medicines with clinically significant anticholinergic or sedative properties. Anticholinergic 
or sedative burden was calculated for each medicine by a hyperbolic function ranging in 
value from 0 to 1, which takes dose into account and also the recommended daily dose. The 
model assumes linear, additive effects for medicines, and no synergism, and comorbidities 
are controlled for in the analysis.  
 
The TBD index was tested in a sample of 3075 community-dwelling older Americans 
(mean age 73.6 ± 2.9 years) who were interviewed and assessed both at home and at a 
clinic (Hilmer et al 2007a). Physical function, attention and concentration were tested, and 
the association of TDB with these measures was determined. Increasing anticholinergic and 
sedative burden were associated with poorer physical and cognitive functions. Adding one 
unit of medicine burden affected physical function as much as three or four physical 
comorbidities would have, and a greater or half the effect of anxiety, depression, or 
cognitive impairment, depending on the measure used. The model is only an estimate of 
actual effects, as the authors note, but simply calculating a total sum of comorbidities may 
not describe participants with complex health problems, as noted in the editorial for this 
article (Agostini 2007). Also, the study participants were independently living older people 
apparently in relatively good condition, so the results may be quite different in e.g. frail, 
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institutionalised populations. A strength of the study is that the TDB index takes dose into 
account. Still the calculation of the index seems rather complex, as recommended and taken 
doses need to be determined. If it could be made into a computer program, the process 
would be easier and the advantages of the model could be fully utilized to give a more 
comprehensive estimate of total medicine burden.  
 
5.4 Anticholinergic lists based on SAA measurements 
 
Tune et al (1992) investigated 10 nM dilutions of 25 commonly used medicines with the 
radioreceptor assay, and measured anticholinergic activity for each, giving a list of SAA 
values and medicines. Included were quite a number of commonly used medicines that are 
not generally considered anticholinergic, but which showed low SAA levels in the assay. 
The cumulative effect of these medicines when taken together may have clinical 
implications. Whether the 10 nM dilutions of the parent compounds without their 
metabolites reflect reality, especially when there are inter-individual differences in 
medicine absorption and metabolism, is not known. But, as a comment to the article 
pointed out, the metabolites of these medicines may not matter from the central cholinergic 
blockade point of view, as metabolites are usually more water-soluble than their parent 
compounds, and therefore may not penetrate the blood-brain barrier so well (Ball 1993). 
 
Chew et al (2008) measured the anticholinergic activity of 107 medicines with the Tune 
and Coyle (1980) SAA assay to publish their anticholinergic list. They diluted the standard 
medicine preparations with medicine free serum to six clinically relevant concentrations 
that are commonly used in older people in long-term care facilities (as according to a 
pharmacy provider in the US). Their goal was to help clinician decision making by offering 
anticholinergic activity values for these medicines at different doses, as medicine use alone 
(yes/no) does not give enough information to find those at risk for adverse effects from 
anticholinergics.  
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Pure preparations of the investigated medicines were dissolved and then diluted to the 
desired concentrations in commercial, medicine-free human serum (Chew et al 2008). 
Interfering effects from the solvents were investigated, and solvents were used only at 
concentrations known not to disturb binding of TQB. Of the investigated 107 medicines, 22 
had dose-dependent anticholinergic activity with all tested concentrations, and 17 only at 
the highest concentration. The resulting in vitro activities may be used in clinical practice, 
but it is unclear, how well stable concentrations of these medicines measured in vitro can 
ever describe the effects in living human patients, especially as blood-brain barrier 
penetration of medicines may change with advancing age.  
 
5.5 Combining different anticholinergic lists 
 
During the literature search, 17 anticholinergic lists were obtained. Some of these lists were 
based on published literature (Peters 1989; Flacker et al 1998; Mintzer and Burns 2000; 
Roe et al 2002; Caeiro et al 2004; Han et al 2008; Uusvaara et al 2009), some were based 
on SAA measurement values (Tune et al 1992; Mulsant et al 2003; Chew et al 2008), some 
were based on expert opinion (Carnahan et al 2006; Laroche et al 2007), and some were 
based on a combination of expert opinion and either literature or SAA assay values (Han et 
al 2001; Lu and Tune 2003; Minzenberg et al 2004; Ancelin et al 2006; Rudolph et al 
2008). Most of these lists were not complete, meaning that they only listed medicines, 
which were used by the patient population in their study, or that they listed medicines most 
commonly used in a defined population. When the 17 lists were combined, a table of 
anticholinergic medicines was obtained (Appendix 2). Some medicines appeared only on 
one list like e.g. timolol, while for others there was more consensus, with amitriptyline 
appearing on 16 lists of the 17 investigated. Medicines appearing on at least eight lists are 
listed in Table 3. Altogether 278 medicines were listed on these published lists combined, 
and of those almost half (126) appeared only on one of the lists. 131 medicines appeared on 
two to seven lists, and 21 appeared on at least eight lists. 
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Table 3. Anticholinergic medicines most often mentioned on 17 lists of anticholinergic 
medicines (Peters 1989; Tune et al 1992; Flacker et al 1998; Mintzer and Burns 2000; Han 
et al 2001; Roe et al 2002; Lu and Tune 2003; Mulsant et al 2003; Caeiro et al 2004; 
Minzenberg et al 2004; Ancelin et al 2006; Carnahan et al 2006; Laroche et al 2007; Chew 
et al 2008; Han et al 2008; Rudolph et al 2008; Uusvaara et al 2009). 
appears on 
how many 
lists?
amitriptyline 16
diphenhydramine 12
imipramine 12
oxybutynin 12
thioridazine 12
hydroxyzine = hydroxine 11
atropine = L/D-hyoscyamine 10
chlorpromazine 10
doxepin 10
ranitidine 10
benztropine 8
chlorpheniramine 8
codeine 8
diazepam 8
digoxin 8
furosemide 8
meclizine = meclozine 8
nortriptyline 8
olanzapine 8
promethazine 8
trihexylphenidyl = benzhexol 8  
 
 
6 RESULTS OF THE EMPIRICAL RESEARCH 
 
The patient data were analysed with Excel and NCSS 2007 and medicine use and 
anticholinergic use were quantified. This data and the mortality analysis are presented in 
the following chapters. 
 
 
  
48 
6.1 Patient sample 
 
Of the 1444 eligible patients in the 53 long-term care wards included in the study, 1004 
residents (70 %) were included in the analysis (Figure 4). Of the total patient population, 
357 residents (25 %) did not give consent to participate, and medicine or mortality data was 
not available for 83 patients (5 %). The women in the study (n = 745) were older  
(p < 0.001) than the men (n = 241), as tested with the t-test, which assumes normal 
distribution for the patient sample ages. The mean (± SD) age was 83.35 (± 9.99) years for 
the women and 75.11 (± 11.48) for the men.  
 
1444 eligible residents (100 %)
consent not
given: 357 
residents
(25 %)
1087 residents (75 %)
medication
data not
available: 35 
residents
(2 %)
1052 residents (73 %)
1004 residents (70 %)
mortality data 
not available: 
48 residents
(3 %)
 
 
Figure 4. The sampling frame of patient information in the current study. From the original 
1444 residents, 70 % were included in the final analysis. 
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6.2 Medicine use in the patient sample 
 
Medicine use among the 1004 patients included in the analysis was investigated. The 1004 
patients in the study were using a mean (± SD) number of 7.1 ± 3.4 medicines regularly 
(median 7 medicines, range 0-20). The distribution of medicine use is shown in Figure 5. 
Altogether 65.0 % (n = 653) were using at least six medicines or more regularly and 31.5 % 
(n = 316) were using at least nine medicines. When those medicines that are taken when 
required were also counted, the rates were 86.7 % (n = 870) using six or more medicines 
and 60.6 % (n = 608) using nine or more medicines. 
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Figure 5. Medicine use in the study population. The 1004 patients were using a mean  
(± SD) number of 7.1 ± 3.4 regular medicines (median 7.0, range 0-20 medicines).  
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6.3 Use of anticholinergic medicines in the patient sample 
 
The study participants were using 29 different medicines that are listed as anticholinergic in 
the ARS tool (Rudolph et al 2008). The numbers of people using them either regularly or 
when required are shown in Figure 6. These medicines and their ARS scores and official 
indications according to the Finnish National Agency of Medicines website are listed in 
Table 4.  
 
Anticholinergic medicine use (1004 patients)
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amitriptyline + chlordiazepoxide
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notriptyline
tolterodine
oxybutynin
perphenazin
amantadine
pramipexole
selegiline
trazodone
entacapone
chlorpromazine
paroxetine
thioridazine
baclofen
loperamide
clozapine
ranitidine
quatiapine
amitriptyline
cetirizine
levodopa + carbidopa
tizanidine
olanzapine
mirtazapine
metoclopramide
hydroxyzine
haloperidol
risperidone
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e
d
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e
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Figure 6. Anticholinergic medicine use in the study population. The numbers of people 
using a medicine regularly are shown with the blue bars, and the people using the medicine 
when required are shown with the orange bars. 
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Table 4. Anticholinergic medicines used by the study participants. Official Finnish 
indications and the ARS scores (Rudolph et al 2008) are listed for each medicine. 
medicine ARS score indications
amantadine
2
Parkinson's disease,
prevention and treatment of influenza type A
amitriptyline
3
depression, sleeplessness with depressive symptoms,
chronic pain (e.g. fibromyalgia, neuropathic pain),
prevention of migraine and tension headache
amitriptyline + 
chlordiazepoxide
3
mild depression with sleeplessness
baclofen 2 spasticity
cetirizine 2 allergy
chlorpromazine
3
psychosis, acute restlessness, agitation,
severe nausea, adjuvant treatment for severe pain
clozapine
2
treatment resistant schizophrenia, treatment resistant 
psychotic disturbances in Parkinson's disease
entacapone 1 Parkinson's disease 
haloperidol 1 long-term care of psychoses
hydroxyzine
3
adult anxiety, urticaria and itching,
sleeplessness with allergic symptoms
levodopa + decarboxylase 
inhibitor 1
Parkinson's disease 
loperamide 2 acute and chronic diarrhoea
loratadine 2 allergy
metoclopramide 1 nausea, gastro-oesophageal reflux
mirtazapine 1 depression 
nortriptyline 2 unipolar and bipolar depression
olanzapine 2 schizophrenia, bipolar disorder
oxybutynin 3 incontinence
paroxetine
1
severe depression, compulsive disorder, panic disorder
fear of social situations, anxiety,
acute stress reactions from trauma
perphenazin 3 psychosis, schizophrenia, severe nausea
pramipexole 1 Parkinson's disease, Restless legs syndrome
quetiapine 1 schizophrenia 
ranitidine
1
ulcers, reflux oesophagitis, gastro-oeasophagal reflux,
gastrinoma
risperidone
1
schizophrenia, bipolar disorder, psychotic symptoms in 
dementia, severe behavioural disturbances in children
selegiline 1 Parkinson's disease
thioridazine 3 schizophrenia
tizanidine 3 muscular spasms, spasticity
tolterodine 2 incontinence
trazodone
1
depression, schizoaffective psychosis, sleeplessness with 
depressive symptoms
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Anticholinergic medicines in regular use were identified from the patient medicine lists 
with the ARS tool and each patient’s ARS score was calculated. As in the original Rudolph 
et al (2008) article, patients were stratified by the ARS score into groups of score zero, 
score one to two, and score three or more. Of the 1004 patients in the study, 455 individuals  
(45.3 %) were not using any anticholinergic medicines, and had an ARS score of zero. 
More than half of the patients (54.7 %) were using at least one anticholinergic medicine. 
Altogether 363 patients (36.2 %) had a mild anticholinergic load, i.e. an ARS score of one 
or two, and 186 patients (18.5 %) had a high load with an ARS score of three or higher. 
The distribution of the ARS scores in the study population is shown in Figure 7. The mean 
ARS score (± SD) was 1.2 ± 1.5, the median score was one and the mode score of the 
sample was zero. The range of the scores was 0-10. 
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Figure 7. Anticholinergic risk scale (ARS) score distribution in the study population. More 
than half (54.7 %) of the patients were using at least one anticholinergic medicine. 
  
53 
 
Three anticholinergic lists (Tune et al 1992 combined with Lu & Tune 2003; Rudolph et al 
2008; Uusvaara et al 2009) were used to classify the study patients into anticholinergic 
users or non-users based on having one or more of medicines in the list in their regular 
medicine regimen. Patient groups identified as users (having one or more anticholinergic 
medicine on a given list) or non-users (having no anticholinergic medicine listed) and 
overlapping of patient groups identified with different lists are shown in Figure 8. 
 
R udolph et al.
(N=527)
n=56
n= 
42
T une et al.
(N=541)
Uusvaara et al.
(N=548)
n=46
n=280
No anti-
cholinergics
(N=213)
n=163
n=59
n=145
 
Figure 8. The patient population as divided into anticholinergic users and non-users 
according to three anticholinergic lists (Tune et al = Tune et al 1992 combined with Lu and 
Tune 2003; Rudolph et al 2008; Uusvaara et al 2009). Altogether 213 patients were not 
identified as users by any list. All three lists overlap and define 280 patients as 
anticholinergic users, and there is some overlap with any two lists together. However, there 
are 246 patients (145 + 42 + 59) who are only classified as users by one list, leading to 
different interpretations in any clinical studies that the lists might be used in. This figure 
highlights the problem of having no international consensus list of anticholinergics. 
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Altogether 213 patients were not identified as anticholinergic users by any of the three lists. 
There was overlapping of patient groups identified by different lists, and 280 patients were 
identified as anticholinergic users by all three lists. The Rudolph et al (2008) list identified 
56 patients who were also identified by the Tune et al 1992 and Lu and Tune 2003 list. 
There was a 56 patient overlap between Rudolph et al (2008) and Uusvaara et al (2009), 
and 163 patient overlap between Uusvaara et al (2009) and the Tune et al 1992 and Lu and 
Tune 2003 lists. Altogether 246 patients (145 + 42 + 59) were identified as anticholinergic 
users by only one list.  
 
6.4 Comparison of Anticholinergic Risk Scale score groups 
 
For all subsequent analysis, patients were stratified into three groups according to their 
ARS score. Patients with a score of zero were considered to have no anticholinergic burden 
and formed the first group. Patients with an ARS score of one or two formed the “some 
anticholinergic burden” group. The “high anticholinergic burden” group was formed by 
patients with scores of three and higher.  
 
6.4.1 Descriptive statistics 
 
Patient descriptive characteristics are presented in Table 6. Not all information was 
available for all patients, and the numbers of patients in each analysis are mentioned in the 
table. There was a statistically significant difference in patient ages between the burden 
groups, and as can be seen from the age ranges, there were also some younger patients 
among the study population. Nevertheless, mean and median ages were high and very close 
to each other.  
 
There were no differences between the anticholinergic burden groups in gender, being 
widowed, education, nutritional status as measured by MNA, and some diagnoses. There 
were differences in Charlson Comorbidity Index scores, the mean duration of 
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institutionalised care, and mobility. The Chi-square and Kruskal-Wallis tests do not tell, 
which of the groups differs or by how much, however, only that there is a difference 
between the three groups. Stroke, depression, other psychiatric illness, Parkinson’s disease 
and hip fracture were diagnoses, for which there was a difference between patient groups.  
 
When medicine use was investigated between anticholinergic burden groups, there was a 
difference in the total number of regularly taken medicines (Table 5). The patients in the 
studied population were using up to 20 medicines regularly. Polypharmacy, defined as 
using at least nine medicines at the same time (Hajjar et al 2005), was present in half of the 
patients with an ARS score of zero, 23 % of those with an ARS score of one or two, and  
17 % of those with an ARS score of three or more. There was a difference between the 
ARS groups for the number of medicines in use, both with the mean number of regular 
medicines and when stratified by having zero, one to eight, or more than eight medicines in 
regular use. 
 
 
 
Table 5. Medicine use of the study participants (n = 1004) stratified by anticholinergic burden 
based on their Anticholinergic Risk Scale (ARS) score. 
 ARS score  
0 
No burden 
(n = 455,  
45 %) 
ARS score  
1-2 
Some burden 
(n = 363, 
36 %) 
ARS score  
≥ 3 
High burden 
(n = 186, 
19 %) 
p-value 
Number of regular medicines 
Mean (± SD) (n = 1004) 5.8 (± 3.1) 7.8 (± 3.0) 8.8 (± 3.7) <0.01 
median 5 8 8  
range 0-16 2-16 1-20  
     
0 medicines in regular use 12 (3 %) 0 0 <0.01 
1-8 medicines  220 (48 %) 278 (77 %) 155 (83 %)  
More than 8 medicines  223 (49 %) 85 (23 %) 31 (17 %)  
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Table 6. Descriptive characteristics of the study participants (n = 1004) stratified by 
anticholinergic burden based on their Anticholinergic Risk Scale (ARS) score. 
 ARS score  
0 
No burden 
(n = 455) 
ARS score  
1-2 
Some burden 
(n = 363) 
ARS score  
≥ 3 
High burden 
(n = 186) 
p-value 
Age (years) (n = 988) 
Mean (±SD)
 
83.0 (± 10.0) 
(n = 449) 
80.5 (± 11.0) 
(n = 356) 
78.7 (± 12.4) 
(n = 183) 
<0,01 
median 84 82 80  
range 49-104 23-99 36-99  
Gender (%): Female (n = 1002) 353 (78 %) 269 (74 %) 133 (72 %) 0.21 
Marital Status (%) 
Widowed (n = 1004)
 
99 (22 %) 69 (19 %) 48 (26 %) 0.18 
Education (%) 
Primary school or less (n = 1004)
 
224 (49 %) 164 (45 %) 92 (50 %) 0.45 
Documented diagnosis (%) 
Diabetes (n = 828)
 
67 (18 %) 51 (17 %) 38 (25 %) 0.12 
Coronary artery disease (n = 818) 118 (31 %) 74 (26 %) 40 (27 %) 0.32 
Acute myocardial infarction (n = 777)
 
40 (11 %) 32 (12 %) 16 (11 %) 0.97 
Stroke (n = 829)
 
180 (46 %) 119 (42 %) 86 (56 %) 0.02 
Dementia (n = 978)
 
345 (78 %) 269 (75 %) 131 (73 %) 0.39 
Depression (n = 794)
 
75 (21 %) 87 (31 %) 45 (32 %) <0.01 
Other psychiatric illness (n = 779)
 
29 (8 %) 62 (22 %) 33 (23 %) <0,01 
Parkinson’s disease (n = 784) 10 (3 %) 38 (14 %) 13 (9 %) <0.01 
Other neurological disease  
(MS, ALS, etc.) (n = 785) 
38 (10 %) 22 (8 %) 16 (11 %) 0.45 
Rheumatic diseases (n = 788) 37 (10 %) 35 (13 %) 21 (14 %) 0.35 
COPD (n = 796) 57 (15 %) 50 (18 %) 27 (19 %) 0.61 
Stomach or duodenal ulcer (n = 768) 15 (4 %) 15 (6 %) 4 (3 %) 0.47 
Hip fracture (n = 807) 103 (27 %) 87 (31 %) 25 (18 %) <0.02 
Cancer (n = 783) 36 (10 %) 29 (11 %) 20 (14 %) 0.44 
Charlson Comorbidity Index score,       
mean (± SD) (n = 1002) 
2.57 (± 1.51) 
(n = 454) 
2.40 (± 1.64) 
(n = 362) 
2.75 (± 1.64) 
(n = 186) 
<0.03 
median 2 2 3  
range 0-8 0-9 0-9  
Mean duration of institutional care 
(months) (± SD) (n = 786)
 
39.1 (± 34.1) 
(n = 357) 
32.7 (± 32.0) 
(n = 280) 
39.4 (± 34.5) 
(n = 149) 
<0.01 
median 30 24 31  
range 1-182 1-217 1-193  
Mobility - wheel chair/bed bound (%)
 
407 (89.5 %) 301 (83 %) 154 (83 %) <0.01 
MNA (% of those with same ARS)
 
    
<17 4 (1 %) 12 (3 %) 6 (3 %)  
17-23.5 178 (39 %) 135 (37 %) 67 (36 %)  
<23.5 273 (60 %) 216 (60 %) 113 (61 %) 0.14 
MS = multiple sclerosis, ALS = amyotrophic lateral sclerosis, COPD = chronic obstructive 
pulmonary disease, MNA= Mini Nutritional Assessment. 
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6.4.2 Investigating the effect of anticholinergic use on risk of death 
 
The ARS score was included as an explanatory variable, a comorbidity in the Cox 
Proportional Hazard model (Table 7). Other coexisting variables or comorbidities included 
AMI, stroke, COPD, diabetes, age, sex, MNA, cancer and mobility. The model estimates 
the risk of death caused by a given comorbidity while controlling for the effects of the other 
comorbidities included in the analysis. The Charlson Comorbidity Index score could not be 
included in the model, as it also incorporates anticholinergic medicines and some 
comorbidities like AMI (Charlson et al 1987). Therefore the model would not be able to 
control for the contributions of other overlapping comorbidities to give estimates to only 
one comorbidity at a time. The logrank test showed no statistical significance for the model 
(p = 0.3779), and only age, gender, and nutritional status (MNA) were shown to be 
comorbidity variables that affected the five-year mortality that was tested. When a Kaplan-
Meier curve of patient survival in days was plotted from the data, it showed no differences 
between the anticholinergic burden groups, as also shown by the Cox analysis (Figure 9). 
The percentages of patients still alive and those who were dead after a five-year period are 
presented in Table 8. There was no statistically significant difference between the ARS 
score groups. About 80 % percent of all the patients were dead after five years. 
 
Table 7. Adjusted risk of mortality using the Cox Proportional Hazard Model 
 
Independent variable Hazard Ratio (95% CI) p-value 
   
Anticholinergic Risk Scale score 0.99 (0.89-1.10) 0.83 
Acute myocardial infarction 1.02 (0.78-1.35) 0.87 
Stroke 1.03 (0.87-1.22) 0.74 
COPD 1.03 (1.02-1.04)  0.76 
Diabetes mellitus 1.22 (0.97-1.53) 0.09 
Age 1.04 (1.03-1.05) < 0.01 
Gender 1.36 (1.11-1.67) < 0.01 
MNA 1.50 (1.26-1.77) < 0.01 
Cancer 1.20 (0.91-1.57) 0.20 
Mobility (bed bound/wheelchair) 1.30 (0.996-1.71) 0.05 
COPD= chronic obstructive pulmonary disease, MNA= Mini Nutritional Assessment 
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Figure 9. The Kaplan-Meier curve of the Cox mortality analysis, with a five-year 
observation period. The probability of still being alive after a certain time (given in days on 
the x-axis) is very similar in all anticholinergic burden groups (differently coloured grey 
lines). 
 
Table 8. The percentage of study participants (n = 1004) dead and alive at five years. Patients 
have been stratified by their anticholinergic burden based on their Anticholinergic Risk Scale 
(ARS) score. 
 ARS score  
0 
No burden 
(n = 455,  
45 %) 
ARS score  
1-2 
Some burden 
(n = 363, 
36 %) 
ARS score  
≥ 3 
High burden 
(n = 186, 
19 %) 
p-value 
% of patients dead or alive (n = 1004) 
Alive at 5 years 20 22 23 0.57 
Dead at 5 years 80 78 77  
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7 DISCUSSION 
 
The most important findings in both the literature review and the empirical research are 
discussed in these following chapters. Methodological and other limitations are discussed. 
 
7.1  Estimating anticholinergic burden 
 
Several methods for estimating anticholinergic burden were identified from peer-reviewed, 
published literature. The SAA radioreceptor assay developed by Tune and Coyle (1980) 
measures a total sum effect of anticholinergic agents present in the blood, giving a rough 
estimate of individual anticholinergic burden. This estimate can be used to investigate 
peripheral anticholinergic burden, but because it only measures blood content of these 
agents, conclusions about central nervous system burden can only be made with caution. 
Peripheral anticholinergic side effects can limit a patient’s quality of life, but central effects 
have the potential to cause cognitive effects, possibly cognitive impairment (Ancelin et al 
2006). The SAA is only a rough estimate of anticholinergic burden, as agonists can cause 
false positive results by reducing the binding of TQB (Carnahan et al 2002a). Any results 
obtained with the SAA assay must therefore be considered in the context of the patient’s 
overall clinical status. 
 
Of the anticholinergic scoring systems identified in the literature review, four levels of 
anticholinergic medicine potency (0, 1, 2, 3) were used in systems developed by Carnahan 
et al 2002b, Carnahan et al 2006, Ancelin et al 2006, Han et al 2008, and Rudolph et al 
2008. These four categories of potency attempted to describe relative potencies in a user-
friendly manner, as small scores are easy to add up e.g. during patient encounters. These 
categories do not describe relative anticholinergic potencies in detail, however, as even 
within category three anticholinergics in any given list, there are bound to be differences in 
potencies. A continuous potency scoring system might better describe the situation. The 
Minzenberg et al (2004) indexes have scores ranging from zero to over 1400, so its 
practical usefulness may be limited by comprehending huge differences in scores. But these 
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indexes attempt to better describe the actual differences in potencies of anticholinergic 
medicines, and this is a step in a possibly more clinically useful direction. The Hilmer et al 
(2007a) Total Drug Burden index takes also doses of the medicines into account, and 
additive effects of sedatives too. It calculates effects in relation to the dose used, so low 
doses contribute less to the burden, as seems likely to also happen in real life. Calculations 
such as these are complex, however, and are not suitable for quick, face-to-face encounters 
with patients. The Total Drug Burden index does seem promising despite that, as it could 
be automated in a computer program, making analysis quicker and easier for a clinician to 
perform.  
 
All of these scoring systems assume a linear relationship in anticholinergic burden, 
assuming that anticholinergic medicine effects add up in a linear way. The possibly 
synergistic effect has not been taken into account in any system, as it is very difficult to 
predict. This would be an interesting topic for future research, as with better computers and 
a better understanding of body functions, mathematical models of individual medicine 
elimination could possibly be combined with an index like this, giving better estimates of 
how medicines behave in the body, and how likely they may be to cause adverse effects.  
 
Many studies used the SAA assay as a comparison, and all its limitations were also then 
affecting interpretations in those studies. The MMSE tool was commonly used to measure 
cognitive abilities. It does describe the overall cognitive status of an individual, but it is 
only a rather crude measure of memory functions (Thomas et al (2008). This limits 
interpretations made from changes in MMSE scores. 
  
Combining the 17 anticholinergic lists identified in the literature review showed that there 
is very little agreement globally, which medicines are to be considered anticholinergic. This 
highlights the need for an international consensus definition of an anticholinergic medicine 
or an official, validated reference method of measuring anticholinergic potency. 
Differences in medicines available in countries around the world make it more difficult to 
develop a global list, as if a medicine is not available in a given country, clinicians in that 
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country may not be familiar with its use and e.g. frequency of anticholinergic effect 
complaints. Some medicines are generally agreed on to be anticholinergic, as shown by the 
21 medicines identified that are listed on at least eight of the 17 anticholinergic lists. Some 
medicines that appeared only on one list were very old medicines that may not be used 
widely anymore, e.g. some older antihistamines. Anticholinergic lists should therefore be 
updated to better mirror developing formularies in future projects. 
 
As a conclusion from all the literature studied, there is no perfect method available at 
present to estimate anticholinergic burden. Clinical judgment needs to be executed, and all 
these methods should be used with caution. This study offers a glance on currently 
available methods for estimating anticholinergic burden, and highlights some of their 
properties. 
 
7.2  Patients in the empirical study 
 
Our study investigated the medicine use and mortality of patients staying in the Helsinki 
area public hospitals in long-term care wards in September 2003. Generalisations to any 
other patient groups in any other setting must therefore be done with caution. The patient 
sample represented 70 % of all patients in these wards at that time point, which is a good 
percentage. Because some of those patients who were not included in the study declined to 
participate at all (n = 357, 25 %), their data was not available to investigate any differences 
between those that declined and those that agreed to participate. Missing data was the 
reason for exclusion of 83 patients (5 %), so they could not be investigated for differences 
either. Nevertheless, 70 % of the total gives a reasonably good estimate of the whole 
potential population of 1444 patients. Generalising this data to other patient populations 
with matching characteristics may be considered, as the number of patients investigated 
was fairly large, 1004. Other long-term care facilities in different parts of Finland or abroad 
may have different care practices though, so caution must be maintained when drawing 
conclusions. 
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7.3  Medicine use in the patient sample 
 
The observed rates of using six or more (65.0 %) or nine or more (31.5 %) medicines either 
regularly or when required are similar to the rates found by Fialova et al (2005) in Finland, 
as they found that 73.3 % of their sample were using at least six medicines either regularly 
or when required, and 41.2 % were using at least nine. Their study was done on home-
dwelling patients when ours was a study on institutionalised patients, but still the results are 
in the same range.  
 
Because this study was cross-sectional, we have no way of knowing whether the patients 
were still using these prescription medicines the next day, or for how long they had been 
using them before data collection. Interpretations of effects with long time frames like 2-
year mortality must be done with caution because of this. Also, no data was available on 
any OTC medicines or herbal remedies that the patients may have been using on their own. 
However, since the patients were institutionalised, their medicine use is likely to have been 
known by their nurses who filled out the data collection questionnaires. Medicines that 
were recorded as being taken only when required were excluded from the study. This was 
done because there was no information available for how long and how often the patients 
might then have been using them. These exclusions may limit reliability, as the frequency 
of their use was not known, and it could have been very often. Also, excluding topical, 
ophthalmological and otological preparations may have limited the reliability of the study 
in the case of e.g. potentially anticholinergic eye drops. It is difficult to estimate, to what 
extent they will have systemic effects, and therefore they were categorically excluded. All 
in all this study shows how common it is that institutionalised patients are using several 
medicines at the same time. These long medicine lists reflect the high total disease burden 
that these frail, older patients have. This finding of commonly using many medicines may 
warrant more research into the rationality of such medicine use. 
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7.4  Anticholinergic medicine use in the patient sample 
 
We used the Rudolph et al (2008) list to identify anticholinergic medicines. The most 
frequently used anticholinergic medicine was risperidone, which was used almost always 
regularly. A total of 19 % (n = 190) of the patients were using it, which is higher than the 
10 % that was reported by Raivio et al (2007) in their study of older institutionalised 
patients. The laxative loperamide was used only when required in this patient sample, and 
haloperidol and metoclopramide were used mainly when required. Hydroxyzine was used 
quite commonly (7 % of the patients) as a regular medicine rather than only when required. 
This is twice as much as observed by Raivio et al in 2006 (3.5 %) in their study of 
institutionalised older patients. Hydroxyzine has quite strong anticholinergic and sedative 
properties, and should be used with caution especially in older people (Beers et al 1991; 
Beers 1999; Fick et al 2003; Fialova et al 2005). Hydroxyzine is officially indicated in 
Finland for treatment of anxiety in adults, as well as urticaria and itching. It is also 
indicated for sleeplessness if there are also allergic symptoms. Our data does not include 
actual individual indications for any medicines in the study population, making it difficult 
to draw conclusions on reasons for using any given medicine. Stroke, depression, other 
psychiatric illness, Parkinson’s disease and hip fracture were diagnoses, for which there 
was a difference between patient groups stratified by their ARS score. Anticholinergic 
medicines are used in the treatment of Parkinson’s disease and some psychiatric medicines 
have anticholinergic side effects, so the number of anticholinergic medicines may be 
affected by having those diagnoses. 
 
An overall anticholinergic medicine usage rate of 54.7 % was found in the patient 
population. This is in the same range as rates of 15 % (Lechevallier-Michel et al 2004),  
40 % (Landi et al 2007), or 63 % (Han et al 2008) observed in previous studies. The 
patients were stratified according to their ARS score, with score zero forming the “no 
burden” group, scores one and two forming the “some burden” group, and scores of at least 
three forming the “high burden” group. This was the same stratification as Rudolph et al 
(2008) had used, so it was chosen in this study as well for ease of comparison. They 
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showed in their analysis how there was a statistically significant difference in the 
occurrence of anticholinergic side effects when patients were grouped according to the 
stratification described above. It is unclear, however, whether these stratifications are 
clinically sensible apart from having people with no listed anticholinergics form a group. 
 
The ARS list is limited by several factors. It does not take dose into account, and the four 
categories of potencies do not describe relative potencies, as described in a previous 
chapter. Taking dose into account did not seem to matter when comparing an 
anticholinergic scoring system to SAA levels (Carnahan et al 2006), but the SAA has 
limitations here also, as it does not seem to be dose-dependent, as increased doses do not 
always increase measured SAA values. It seems likely that having a higher dose would 
worsen any adverse effects. The ARS list was constructed from 500 most prescribed 
medicines in a health care provider system in Boston, so it does not necessarily describe 
medicines used in any other setting. E.g. biperiden, an anticholinergic agent, is missing 
from the list. It was only used by one of our 1004 patients, so effects of it missing in this 
analysis may not have been dramatic, but still it highlights the problem of different 
formularies in different countries and constructing anticholinergic lists based on only those 
medicines that were used by a given patient population. Adjustments need to be made when 
using tools developed in other countries (Gallagher et al 2007). 
 
Grading of the ARS list was done based on affinity data of the medicines for muscarinic 
receptors, FDA-published rates of their anticholinergic side effects, and literature regarding 
the adverse effects. But as Kwatra (2008) commented on the article, affinity results are 
usually only given for the M1 receptor, limiting reliability. Also the ARS list’s predictive 
value has not been established, as it was only recently published. It has not been used in 
any published studies yet since being introduced to the scientific community. 
 
When the three anticholinergic lists (Tune et al 1992 combined with Lu & Tune 2003; 
Rudolph et al 2008; Uusvaara et al 2009) were used to identify anticholinergic users, the 
problem of having no international consensus was again highlighted. Only 280 patients  
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(28 % of all patients) were identified by all three lists as users, and 213 patients (21 % of all 
patients) were identified as non-users. The other patients were identified as users by only 
two or one list, so of those identified as users, only 35 % were identified by all three lists.  
The lists that were used were chosen based on their different source material, either SAA 
(Tune et al 1992 combined with Lu & Tune 2003), or literature and an American (Rudolph 
et al 2008) or Finnish (Uusvaara et al 2009) formulary. This was done to highlight the 
differences in anticholinergic lists, so this comparison may reflect a worst case scenario. 
Nevertheless, international co-operation is needed to build a consensus anticholinergic list 
and/or scoring system to avoid the problems highlighted by this comparison. 
 
7.5  Statistical analysis of different patient characteristics  
 
Patients were stratified according to their ARS score into three groups: ARS score zero, 
ARS score one to two and ARS score three or more. This stratification was done for ease of 
comparison with the original Rudolph et al (2008) paper, but whether the jump from score 
two to score three is a clinically relevant threshold is unknown at this point. There was a 
difference in the mean number of medicines used by the three groups. People with a higher 
score seemed to also be using more medicines, although definite conclusions cannot be 
drawn from a Kruskal-Wallis analysis, only that there is a statistically significant difference 
between the groups investigated.   
 
All patients staying in the wards in the study were included in the sampling, and patients 
were not excluded because of their age or having dementia, as done in the study by Low et 
al (2008). They excluded patients who had dementia, as they may be especially vulnerable 
to adverse effects of anticholinergic medicines. A large proportion, 76 % of our 
institutionalised patient sample had diagnosed dementia. The mean (± SD) age of our 
patient sample was 83.35 (± 9.99) years for women and 75.11 (± 11.48) for men, and the 
ages ranged from 23 to 104. In general, people in the age group of 65 to 74 have a 
prevalence of 4.2 % and people between ages 75 and 84 have a prevalence of 10.4 % for 
dementia, with over 84-year-olds having a prevalence of 35.0 % (Koskinen et al 2006). The 
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high prevalence of dementia in our sample can be explained by the patients being 
institutionalised, as those with advanced stages of dementia need constant care.  
 
The observed difference in hip fractures between groups, which seems to suggest that 
patients with a zero ARS score had more hip fractures. There was a difference in being bed 
bound, and those with ARS score zero seemed to be more mobility-challenged. Both of 
these effects may be because these zero ARS score patients’ medicine load had been 
lightened when their disabilities developed.  
 
These observed differences in patient characteristics offer comparison points for future 
studies. Also, from these comparisons, explanatory factors were chosen for the mortality 
analysis. 
 
7.6  Mortality analysis  
 
Since we had exact dates of death for all participants included in the analysis, those who 
were still alive at the two-year mortality cut-off time were not censored by just knowing 
that they survived beyond the study time frame, a phenomenon called end-of-study 
censoring (Altman and Bland 1998; Leung et al 1997). The Kaplan-Meier estimator 
describes survival when there is one sample of people, and the analysis is adjusted for 
whether or not an observation in the study is censored. Kaplan-Meier may either 
overestimate or underestimate survival, depending on whether the survival time and the 
censoring time (i.e. end of study) are positively or negatively correlated, respectively. 
Because only times of death were obtained for the patients, they may also have had a 
competing mortality effect, i.e. they died from other reasons than because of the 
investigated cause (Altman and Bland 1998), the use of anticholinergics. In our study, most 
patients were very old, as shown by the medians of ages also being high, not just the means 
as the ranges showed also some very young individuals. Mortality in this old age group is 
quite high, approximately 43 to 46 % 2-year mortality (Raivio et al 2006; Raivio et al 
2007), so most of these old patients would have died by the five-year time point. The cross-
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sectional structure of our study is a limitation to researching mortality effects, as detecting 
and showing an addition to “normal” mortality caused by anticholinergics is very difficult. 
Therefore the results must be interpreted with caution as direct causality cannot be shown, 
only if there are differences in the mortality rates of ARS score groups. 
 
The logrank test that was used in our analysis compares survival functions of samples of 
people. It was used to test whether there were differences in the rate of an event occurring, 
in this case death (Bland and Altman 2004). The logrank test is most likely to detect a 
difference between groups when the risk of an event is consistently greater for one group 
than another. It is unlikely to detect a difference when survival curves cross. When 
analysing survival data, the survival curves should always be plotted. As it could be seen 
from our data, the curves did in fact cross several times, as there were no clear differences 
between curves of different groups. The logrank test showed no statistically significant 
difference. 
 
 When covariates were taken into account, Cox proportional hazard model was used to see 
how different factors might affect the risk of death. Age, gender, and nutritional status were 
significant contributors to the risk of death in our Cox model. Being older, male and 
undernourished increased the risk of death, as seems logical, so the model did work. The 
ARS score failed to affect mortality in our analysis. This could be because using 
anticholinergics is so intertwined with some comorbidities because they are used to treat 
those conditions, and this would limit the power of the prediction tool. This lack of effect 
was also shown in the Kaplan-Meier survival plot, where patient groups with differing 
anticholinergic burden did not differ from each other in survival probability.   
 
Our data included 70 % of the eligible residents in Helsinki nursing homes in September 
2003. The 30 % censored were not included in the analysis. The available data may or may 
not describe them, and any loss of participants means some degree of loss of reliability and 
validity for the study (Altman and Bland 2007). In general, a 70 % response rate is 
considered rather good, but still there is the possibility of bias, rising from the possibility 
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that certain type of people may have been more likely to be excluded from the analysis. 
This would happen if exclusion from the analysis was not random but rather caused by e.g. 
one ward having all their data missing and therefore being totally excluded. This seemed to 
be the case in this study, as when patient identifiers of those excluded were investigated, 26 
patients with consecutive identifiers were found. This may or may not mean, that a defined 
group was excluded. Also, since the patient data were obtained from previous nutritional 
status studies and not from a study design specifically made for mortality analysis, it should 
be considered a convenience sample. 
 
Our cross-sectional study found no association between the use of anticholinergics and 
mortality in our sample of older institutionalised people from the Helsinki area. This may 
mean that there is no effect, or that the possible effect was not shown by our study design 
(Altman and Bland 1995). Because of the limited information available on the duration of 
medicine use offered by our cross-sectional data, it may be that our analysis did not have 
enough power to show a possible effect. Raivio et al (2007) found no association with 
mortality for atypical or conventional antipsychotics in their study, and even when 
investigating the effects of potentially inappropriate medicines as defined by the Beers 
criteria (Beers 1997) for older patients, no association was found (Raivio et al 2006). To 
our knowledge, this is the first study investigating association of anticholinergic medicine 
use with mortality, so it can be seen as a study showing a need for more research into the 
area. Future research should focus on establishing international guidelines or 
recommendations for listing which medicines are anticholinergic, and with those guidelines 
a method for summing up the anticholinergic effects of a patient’s anticholinergic 
medicines could be either devised or updated and developed from the previously published 
methods. With an improved anticholinergic burden tool possible morbidity and mortality 
effects should be studied in a randomised, controlled prospective clinical study. 
Anticholinergics do have adverse effects, but it may be that their effects are not easily 
separated from other factors to estimate any direct effects on mortality that they may have. 
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8 CONCLUSIONS 
 
The literature review showed that there are many methods for estimating anticholinergic 
burden. Anticholinergics are widely used for common ailments, but they may cause 
potentially harmful side effects. Therefore it is important that their use is monitored. A 
simple method for estimating a person’s total anticholinergic burden would be a useful tool 
in clinical practice. One of the most used methods for research purposes is the Serum 
Anticholinergic Activity assay (Tune and Coyle 1980), which measures the total 
anticholinergic burden in blood samples. Correlation between peripheral SAA 
measurements and anticholinergic burden in the CNS has not been proven in large clinical 
trials yet, despite the assay having been available for research for decades. Many studies 
use the SAA as a reference method despite its limitations, as there is no reference method 
for measuring anticholinergicity at present time.  
 
Several anticholinergic scoring systems have been developed in recent years, but none of 
them have become accepted widely. Only some medicines are generally agreed on to be 
anticholinergic, while for some there is conflicting evidence, which makes interpretations 
more difficult. Simply listing medicines as anticholinergic or not is usually not sufficient 
for clinical purposes, as not all medicines are as potent anticholinergics as others. Therefore 
many lists or scores have adopted an approach where at least some form of grading is given 
to medicines to mimic real life differences in potencies. Taking dose into account matters 
perhaps most for modestly anticholinergic medicines, where a high dose may make 
otherwise negligible effects clinically relevant. Factoring dose into a scoring system is 
difficult, however, as the need for calculations and background information increases. No 
list or scoring system so far has become universally accepted, and there are only small 
studies on their use. There is a lot of interest in anticholinergics currently, and scoring 
systems are being developed. More research is needed to establish truly useful tools for 
clinicians for everyday practice. But no matter how good a tool is, sound clinical judgment 
cannot be replaced, as all patients are individuals and their special circumstances need to be 
considered.  
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No association was found between the use of anticholinergics and the risk of death in the 
cross-sectional sample in the empirical research. Anticholinergics may contribute to 
accidents and falls, but it is unclear whether they affect mortality directly. Our study 
population of frail, older institutionalised patients was using a number of anticholinergic 
medicines, and their mean age was high. Because older people may have reductions in 
cognitive and bodily functions as a natural effect of aging, any anticholinergic medicines 
enhancing these reductions may be harmful. The high medicine burden and also the high 
anticholinergic burden in institutionalised older patients found in this study as in many 
others is a potentially alarming trend. More research is needed to investigate the effect of 
this burden, and prescribing practices need to be updated to reduce the unnecessary use of 
medicines.  
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APPENDIX 2. Anticholinergic medicine lists combined.  
a) Based on a literature review / national reference books. b) Based on in vitro measurements of SAA. c) Only medicines used by study participants included. / List not 
complete. d) Based on Tune et al 1992. e) Based on expert opinion. f) Based on Han et al 2001. z = definite central anticholinergic effect, y = possible central 
anticholinergic effect. Relative potencies as defined by authors are given in numbers or descriptions, and the maximum score for each scoring list was 3. 
 
 
Authors:
Peters 
1989
a) c)
Tune et al 
1992
b) c)
Flacker et 
al 
1998
a) c)
Mintzer & 
Burns 
2000
a) c)
Han et al 
2001
a) e)
Roe et al 
2002
a) c)
Mulsant 
et al 
2003
b) c)
Lu and 
Tune 
2003
c) d) e)
Mintzen-
berg et al 
2004
b) e)
Caeiro 
et al 
2004
a)
Ancelin et al 
2006
b) c) e)
Carnahan 
et al 2006
e) 
f)
Laroche et 
al 2007
e)
Han et al 
2008
c) e) f)
Chew 
et al 
2008
b)
Rudolph et 
al 2008
a) c) 
e)
Uusvaara 
et al 2009
a) 
c)
appears on 
how many 
lists?
acamprosate calcium x 1
acepromazine = acetylpromazine 3 1
aceprometazine 3 x 2
acetazolamide x 1
alimemazine = trimeprazine 2 x 2
alizapride x x 2
alprazolam x y x 3 1 1 detectable 7
alverine 2 1
amantadine x x x 1 2 4
ambutropium + oxazepam x 1
amilsulpride = sultopride x 1
amineptine = maneon x 1
amitriptyline x x x x x z x x x 3 3 x 3 3 3 high 16
amitriptyline + perphenazine x 1
amoxapine x x x x 3 x 6
amoxicillin 0,5 1
ampicillin x x 1 3
atenolol 1 1 2
atropine = L/D-hyoscyamine x x x x x x 3 3 3 3 10
azatadine x 1
azathioprine x x 1 3
baclofen x 2 2 3
belladonna alkaloids x x x x 3 x 3 7
benazepril 1 1
benzoctamine x 1
benztropine x x x x x x 3 3 8
betaxolol 1 1
biperiden x x x x 1 5
bromocriptine 1 1
brompheniramine x y 3 x 4
buclizine x 1
bupropion = amfebutamone y x 1 3
butaverine x 1
butylscopolamine = butilescopolamine x 1
cabergoline x 1
captopril x y x 1 detectable 5
carbamazepine 2 1 2
carbidopa 1 1
carbinoxamine x 3 x 3
carisoprodol 3 1
cefamandole x x 1 3
cefoxitin = mefoxin x x 1 3
celecoxib 0,5 1
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cephalexin 0,5 1
cephalothin x x 1 3
cetirizine 2 2 2
chlordiazepoxide x x x 1 1 5
chlorpheniramine x x z 3 3 x 3 3 8
chlorpromazine x x x x x 3 x 3 2 3 10
chlorthalidone x y x 1 4
cimetidine x x y x 2 2 6
cinnarizine x 1
cisapride x 1
citalopram x 1 2
clebopride x 1
clemastine = meclastin x x 3 3
clidinium x x x high 4
clidinium-chlordiazepoxide x 1
clindamycin x x 1 3
clomipramine x x x 3 3 x 6
clonazepam 1 1
clorazepate = chlorazepate x y x 3 1 5
clozapine x x x x 3 3 2 7
codeine x x 1 x 2 1 1 detectable 8
colchicine x y 3 3
corticosterone x x 2
cortisone 1 1
cyamemazine x x 2
cyclizine x x 2
cyclobenzaprine x x x 2 1 2 6
cyclopentolate x x 2
cycloserine x x 1 3
cyclosporine x x 1 3
cyproheptadine x x 2 x 3 5
dantrolene x 1
darifenacin 3 1
Deadly Nightshade (myrkkykoiso) 1
desipramine = desmethylimipramine x x x x 3 2 2 7
dexamethasone x x 1 3
dextromethorphan 1 1
diazepam x 1 y x 1 1 0,5 detectable 8
dicyclomine = dicycloverine x x x 3 3 3 6
digitoxin 1 1
digoxin x x y x 3 1 0,5 detectable 8
dihexyverine x 1
diltiazem x x 1 3
dimenhydrinate x 3 x 3 x 5
diphenhydramine x x x x z x x 3 x 3 2 3 12
diphenoxylate x 0,5 2
diphenoxylate-atropin x 1
dipyridamole x y x 1 detectable 5
disopyramide x x x y 2 x detectable 7
distigmine x 1
domperidone x 1
donepezil 0,5 1
dosulepin = dothiepin x x 2
doxepin x x x x x 3 x 3 3 detectable 10
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doxylamine x x 2
duloxetine 0,5 1
Echinacea angustifolia x 1
emepronium x high 2
empracet® = paracetamol-codeine 2 1
entacapone 1 1
escitalopram 1 1
estazolam 1 1
ethopropazine = profenamine x 1
ethylbromide = bromoethane x 1
etoperidone x 1
famotidine x 1 2
felbamate x 1
fentanyl 1 1 0,5 3
fexofenadine 2 1
flavoxate x x x x 3 5
flunitrazepam x x 2
fluoxetine x 1 1 1 4
flupentixol x 1
fluphenazine x x x x 1 x 3 7
flurazepam x x 1 3
fluticasone-salmeterol 1 1
fluvoxamine 1 x 1 3
furosemide x x y x 3 1 0,5 detectable 8
gentamycin x x 1 3
glutethimide x 1
glycopyrrolate x 1
guaifenesin 1 1
haloperidol x x 2 x x 1 6
Henbane (hullukaali) x 1
homatropine x x x 3 4
hydralazine x y x 1 4
hydrochlorthiazide x 1
hydrocodone 2 0,5 2
hydrocortisone x y x 1 4
hydroxyzine = hydroxine x x x x z x 3 3 x 3 high 11
hyoscyamine = L-atropine x x z 3 3 3 6
imipramine x x x x x x x 3 3 x 3 3 12
indapamide x 1
ipratropium (inhaler) x x x z x detectable 6
isosorbide 1 1
isosorbide dinitrate x x y x 1 detectable 6
isosorbide mononitrate 1 detectable 2
ketorolac 1 1
ketotifen ophthalmic 1 1
lansoprazole 0,5 1
levodopa + carbidopa x 1 2
levofloxacin 0,5 1
levomepromazine = methotrimeprazine x 3 2 x high 5
lithium 1 1
loperamide 1 1 1 2 4
loratadine 1 2 2
lorazepam 1 1
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loxapine x 2 2
maprotiline x x x 3 x 5
mebeverine x 1
meclizine = meclozine x x x x z 3 x 3 8
melperone = methylperone x 1
memantine x 1
mequitazine x 1
mesoridazine x x 2
metformin 0,5 1
methadone 2 1
methantheline x 1
methocarbamol 1 1 2
methscopolamine x 1
methyldopa x 1
methylprednisolone 1 1
metoclopramide x 3 1 detectable 4
metopimazine x 1
metoprolol 1 1 2
mianserin x 1
midazolam 1 1
milnacipran x 1
mirtazapine x 1 1 3
moclobemide x 1
molindone 2 1
morphine 1 1 1 3
nefazodone x 1 2
neostigmine x 1
nifedipine x x y x 1 detectable 6
nizatidine 1 1
nortriptyline x x x x x 3 3 2 2 8
olanzapine x x x 1 1 2 2 8
ondansetron x 1
opipramol 3 1
orphenadrine x x x x 3 3 high 7
otilonium x 1
oxazepam x x 1 3
oxcarbazepine 2 1
oxomemazine x 1
oxybutynin x x x x x x 3 3 x 2 3 high 12
oxycodone x x 1 1 4
pancuronium x x 1 3
paroxetine 2 x x 1 2 2 1 7
periciazine = propericiazine x high 2
perphenazine x x 1 x 2 3 6
pethidine = meperidine x x 2 2 4
phenelzine x x x 1 4
phenindamine x 1
pheniramine x 1
phenobarbital x x 1 3
phenytoin 0,5 1
phloroglucinol x 1
pilocarpine x 1
pimethixene x 1
pimozide x x x 2 4
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pinaverium x 1
piperacillin x x 1 3
pipotiazine x 1
pramipexole x 1 2
pramiverine x 1
prednisolone x x x 1 4
prednisone y 1 2
prifinium x 1
procainamide x 1
prochlorperazine x x x 1 2 2 detectable 7
procyclidine x x 3 3
promazine x x 2
promethazine x x x x x 3 x 3 8
propantheline x x 3 2 4
propinoxate = propinox x 1
propiverine x 1
propoxyphene 2 0,5 2
protriptyline x x x 3 4
pseudoephedrine-triprolidine 2 1
pyridostigmine x 1
pyrilamine = mepyramine x 3 2
quetiapine x x 2 1 1 5
quinidine x x x y detectable 5
quinupramine x 1
ranitidine x x 2 y x 2 2 1 1 detectable 10
reboxetine x 1
risperidone 1 x x 1 1 5
robitussin = dextromethorphan or guaifenesin 1 1
scopolamine = hyoscine x x x 3 x 3 6
selegiline x 1 2
sertindole x 1
sertraline x x 1 1 4
solifenacin x 1
sulpiride x 1
temazepam 1 1 2
theophylline x x y x 2 1 detectable 7
thioridazine x x x 3 x x x x 3 3 3 3 12
thiothixene x x x 1 3 5
tianeptine x 1
tiapride x 1
ticrocillin x x 2
tiemonium iodide x x 2
timolol x 1
tiropramide x 1
tizanidine x 3 2
tobramycin x x 2
tolterodine x 3 x 3 3 2 detectable 7
topiramate 0,5 1
tramadol 1 2 detectable 3
trandolapril 1 1
trazodone x x x 1 1 5
triamcinolone 1 1
triamterene y x 1 detectable 4
triazolam 1 1 2
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trifluoperazine x x 1 3 4
trifluperidol x 1
triflupromazine x 1
trihexylphenidyl = benzhexol x x x x x 3 3 3 8
trimebutine x 1
trimethobenzamide x 1
trimipramine x x x x 3 3 x 7
triprolidine x x 2
tropatepine 3 1
tropicamide x x 2
trospium x 1
valproic acid, divalproex sodium x x 1 3
vancomycin x x 1 3
warfarin = coumadin x x y x 1 detectable 6
venlafaxine x 1 2
veralipride x 1
viloxazine x 1
ziprasidone 1 1
zotepine x 1
zuclopenthixol x 1
 
 
 
 
